Compound for regulating and controlling activity of 15-PGDH and preparation method thereof

CN119013280APending Publication Date: 2024-11-22SCINNOHUB PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033702.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-21
Filing Date
2023-04-13
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing 15-PGDH inhibitors and agonists have limitations in treating related diseases, and it is difficult to effectively regulate the activity of 15-PGDH, which affects the therapeutic effect.

Method used

A new compound is provided. The specific structure includes an aromatic ring, an aromatic heterocyclic ring or an unsaturated aliphatic heterocyclic group. Through a specific functional group combination and connection method, a compound with the ability to regulate 15-PGDH activity and its salt or composition is formed. , used to prepare medicines.

Benefits of technology

The compound can effectively inhibit or activate 15-PGDH and is used to treat a variety of 15-PGDH-related diseases, including fibrosis, inflammatory diseases and cardiovascular diseases, significantly improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013280A_ABST
    Figure CN119013280A_ABST
Patent Text Reader

Abstract

Disclosed are a compound of formula (I) having the activity of regulating 15-PGDH, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug thereof, a pharmaceutical composition containing the same, and a use for preparing a 15-PGDH inhibitor. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

A compound for regulating 15-PGDH activity and preparation method thereof Technical Field

[0001] The present application relates to a compound for regulating 15-PGDH activity and a method for preparing the same, and specifically to a compound for regulating 15-PGDH activity that can be used as a drug, and a pharmacologically acceptable salt thereof, a composition containing the compound or its salt, and its use in preparing drugs, belonging to the field of medicinal chemistry. Background Art

[0002] 15-hydroxyprostaglandin dehydrogenase (15-PGDH) belongs to the evolutionarily conserved superfamily of short-chain dehydrogenases / reductases (SDRs) and is designated SDR36C1 according to the most recently approved human enzyme nomenclature. Based on existing research, most of the in vivo activity can be attributed to type I 15-PGDH, encoded by the HPGD gene. 15-PGDH plays an important role in the inactivation of active prostaglandins (PGD2, PGE1, PGE2, PGF2α, PGI2, etc.), hydroxyeicosatetraenoic acids (HETEs), and lipid mediators of inflammation resolution (RvD1, RvD2, RvE1, MaR1, LXA4, etc.) (hereinafter referred to as 15-PGDH substrates) (e.g., by catalyzing the oxidation of the 15-hydroxyl group of PGF2α to produce 15-keto-PGF2α). These 15-PGDH substrates exert their functions through specific receptors on target cells. Among them, prostaglandins PGE1, PGE2, PGF2α, and PGI2 are commonly used to evaluate 15-PGDH activity. For example, PGDH activity is evaluated by measuring the ketone metabolite at the 15-hydroxyl group of PGF2α (Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 1, 291-299).

[0003] The receptors for 15-PGDH substrates are widely and differentially distributed throughout the body, and the diversity of receptor types, signaling, and expression distribution contributes to the diversity of its functions. For example, PGE1 acts on blood vessels and platelets, increasing blood flow through vasodilation and platelet aggregation inhibition, and is therefore commonly used to treat diseases such as chronic arterial occlusion (thromboangiitis obliterans (TAO) or arteriosclerosis obliterans (ASO)) and skin ulcers. PGF2α has uterine contraction and intraocular hypotensive effects, and its derivatives are used as therapeutic agents for glaucoma. PGD2 can inhibit inflammation by enhancing the barrier function of pulmonary vessels. In addition, PGE2 has vasodilatory effects and has multiple effects related to blood pressure, pain, bone formation and cell growth, stem cell differentiation, as well as anti-fibrosis and anti-inflammatory effects. PGI2 inhibits platelet activation and relaxes vascular smooth muscle, and its derivatives are used as therapeutic agents for chronic arterial occlusion and primary pulmonary hypertension. Inflammation-resolving lipid mediators (RvD1, RvD2, RvE1, MaR1, LXA4, etc.) inhibit the migration / activation of neutrophils and accelerate the apoptosis of neutrophils. In addition, they are indispensable in increasing the phagocytic activity of macrophages to effectively remove apoptotic neutrophils / tissue fragments remaining in the inflammatory site. These functions can promote inflammation and maintain homeostasis in the organism. It is reported that these inflammation-resolving lipid mediators can show medicinal efficacy in various types of pathological models (such as mouse pneumonia model, colitis model and liver injury model).

[0004] Recent studies suggest that 15-PGDH inhibitors and 15-PGDH agonists may have therapeutic value. A recent study demonstrated that increased 15-PGDH expression plays a role in protecting against thrombin-mediated cell death. 15-PGDH is known to inactivate prostaglandin E2 (PGE2), a downstream product of COX-2 metabolism. PGE2 has been shown to be beneficial in various biological processes, such as maintaining hair density, promoting skin wound healing, and promoting bone formation.

[0005] 15-PGDH is an important enzyme in the inactivation of 15-PGDH substrates and is involved in a wide range of in vivo effects. 15-PGDH inhibitors can be used to prevent or treat diseases related to 15-PGDH and / or 15-PGDH substrates, and / or when it is necessary to increase the substrate level of 15-PGDH in a subject.

[0006] As mentioned above, some substrates of 15-PGDH have the effects of anti-fibrosis, anti-inflammation, blood flow improvement, growth promotion, promotion of stem cell increase, promotion of smooth muscle contraction / relaxation, influence on bone metabolism and immunosuppression. Therefore, 15-PGDH inhibitors can effectively treat or prevent fibrosis (such as pulmonary fibrosis (idiopathic pulmonary fibrosis, etc.), liver fibrosis, kidney fibrosis, myocardial fibrosis, scleroderma and myelofibrosis), inflammatory diseases (such as chronic obstructive pulmonary disease (COPD), acute lung injury, sepsis, asthma and lung disease, inflammatory bowel disease (such as ulcerative colitis and Crohn's disease), peptic ulcer (such as NSAID-induced ulcer), autoinflammatory diseases (such as Behcet's disease), vasculitis syndrome, acute liver injury, acute kidney injury, non-alcoholic fatty liver disease (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndrome (such as chronic prostatitis / chronic pelvic pain syndrome)). syndrome), cardiovascular diseases (such as pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, chronic kidney disease, renal failure, stroke and peripheral circulatory disorders), trauma (such as diabetic ulcers, burns, pressure ulcers, acute mucosal injury (including Stevens-Johnson syndrome and mucosal injury associated with anticancer chemotherapy agents such as alkylating agents, DNA synthesis inhibitors, DNA gyrase inhibitors, antimetabolites, mucosal injury associated with cellular or humoral immunotherapy, mucosal injury associated with graft-versus-host disease, such as mucositis or stomatitis), autoimmune diseases (such as multiple sclerosis or rheumatoid arthritis), graft-versus-host disease (GVHD), hair growth (such as inflammatory bowel disease), and inflammatory bowel disease. Growth) disorders, osteoporosis, ear diseases (such as hearing loss, tinnitus, vertigo and balance disorders), eye diseases (such as glaucoma and dry eyes), diabetes, underactive bladder, neutropenia, nervous system diseases caused by stem cell, bone marrow or organ transplantation (such as mental neurological diseases, neuropathy, neurotoxic diseases, neuropathic pain and neurodegenerative diseases), muscle regeneration diseases (such as muscle atrophy, muscular dystrophy and muscle damage); in addition, 15-PGDH inhibitors can also be used to promote cervical ripening.

[0007] The compounds and pharmaceutically acceptable salts thereof provided in the present application further meet the demand for small molecules that inhibit 15-PGDH activity.

[0008] Summary of the Invention

[0009] The present application provides a compound represented by formula (I), a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof (such as a hydrate), or a prodrug thereof:

[0010] Ring A is selected from aromatic rings, aromatic heterocycles, and unsaturated aliphatic heterocycles,

[0011] L and G are each independently selected from C1 to C 10 A chain hydrocarbon group, or L, G and the N atom to which they are connected together form a cyclic group, wherein the cyclic group is a 3-12 membered saturated aliphatic heterocycle or a ring formed by combining a 3-12 membered saturated aliphatic heterocycle and a benzene ring,

[0012] o is selected from 0, 1, 2, 3,

[0013] R 1 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, halogen, cyano, =O, imino, amine, ester, aldehyde, carboxyl, amide, C3-C8 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, 3-8 membered saturated heterocyclic ring, or when o is selected from 2, 3, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 3- to 8-membered alicyclic group or a 3- to 8-membered alicyclic group,

[0014] is a single bond or a double bond, and when When it is a double bond, X and Y are each independently selected from CR B or N; when When it is a single bond, X and Y are CR C R D ,

[0015] R A 、R B 、R C 、R D Each is independently selected from hydrogen, hydroxyl, halogen, amino, cyano, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl;

[0016] wherein the aromatic heterocycle, saturated aliphatic heterocycle, unsaturated aliphatic heterocycle, and aliphatic heterocyclic group each independently contain 1 to 3 heteroatoms, the heteroatoms being independently selected from N, O, and S, and the saturated aliphatic heterocycle contains at least 1 nitrogen atom;

[0017] The L, G, R 1 Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, aldehyde, amine, imine, halogen, cyano, ester, carboxyl, amide, =O, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

[0018] Furthermore, in certain embodiments of the present application, L and G are each independently selected from C1 to C 10Alkyl, wherein L and G are optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, aldehyde, amine, imine, halogen, cyano, ester, carboxyl, amide, =O, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, and 5-10 membered heteroaryl;

[0019] Preferably, L and G are each independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, hydroxymethyl, hydroxyethyl, and hydroxypropyl.

[0020] In some embodiments, Ring A is selected from an aromatic ring, an aromatic heterocycle, an unsaturated aliphatic heterocycle,

[0021] L and G are each independently selected from C1 to C 10 A chain hydrocarbon group, or L, G and the N atom to which they are connected together form a cyclic group, wherein the cyclic group is a 3-12 membered saturated aliphatic heterocycle or a ring formed by combining a 3-12 membered saturated aliphatic heterocycle and a benzene ring,

[0022] o is selected from 0, 1, 2, 3,

[0023] R 1 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, halogen, cyano, =O, imino, amine, ester, aldehyde, carboxyl, amide, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, 3-8 membered saturated heterocyclic ring, or when o is selected from 2, 3, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 3- to 8-membered alicyclic group or a 3- to 8-membered alicyclic group,

[0024] is a single bond or a double bond, and when When it is a double bond, X and Y are each independently selected from CR B or N; when When it is a single bond, X and Y are CR C R D ,

[0025] R A 、R B 、R C 、R D Each is independently selected from hydrogen, hydroxyl, halogen, amino, cyano, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl;

[0026] wherein the aromatic heterocycle, saturated aliphatic heterocycle, unsaturated aliphatic heterocycle, and aliphatic heterocyclic group each independently contain 1 to 3 heteroatoms, the heteroatoms being independently selected from N, O, and S, and the saturated aliphatic heterocycle contains at least 1 nitrogen atom;

[0027] The L, G, R 1 Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, aldehyde, amine, imine, halogen, cyano, ester, carboxyl, amide, =O, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

[0028] In certain embodiments of the present application, the Is a single bond, and X, Y are CR C R D , the R C 、R D Selected from hydrogen, hydroxy, cyano, halogen, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

[0029] In certain embodiments of the present application, the is a double bond, and at least one of X and Y is selected from CR B , the R B is selected from hydrogen, hydroxyl, cyano, halogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; preferably, the R B Selected from hydrogen, hydroxy, cyano, halogen, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

[0030] In certain embodiments of the present application, the R A Selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, -NH2, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

[0031] In certain embodiments of the present application, the ring A is selected from a 6-10 membered aromatic ring, a 5-10 membered aromatic heterocycle, and a 6-8 membered unsaturated aliphatic heterocycle; preferably, the aromatic ring and the aromatic heterocycle are monocyclic or fused, the unsaturated aliphatic heterocycle is a monocyclic, and the aromatic heterocycle and the unsaturated aliphatic heterocycle each independently contain 1 to 3 heteroatoms, and the heteroatoms are independently selected from N, O, and S.

[0032] In certain embodiments of the present application, the ring A is selected from a 6-10 membered aromatic ring, or a 5-10 membered aromatic heterocycle containing 1-3 heteroatoms (preferably 1-2 heteroatoms), and the heteroatoms are independently selected from N, O, and S. In some preferred embodiments, the ring A is a benzene ring, or a 5-10 membered aromatic heterocycle containing 1-2 heteroatoms, and the heteroatoms are independently N or S.

[0033] In certain embodiments of the present application, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 3-8 membered (e.g., 5-7 membered or 5-6 membered) aliphatic heterocyclic group. In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 5-7 membered (preferably 5-6 membered) aliphatic heterocyclic group containing 1-3 heteroatoms (preferably 1-2 heteroatoms, or 1 heteroatom), wherein the heteroatoms are independently N, O or S (preferably N). In some preferred embodiments, the R 1 Optionally substituted by one or two independently selected from =O, C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl). In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a saturated or unsaturated 5-6 membered cyclic amide group, which is unsubstituted or further substituted by a C1-C6 alkyl group (preferably a C1-C5 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group). In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a saturated or unsaturated 5- to 6-membered cyclic amide group, wherein the nitrogen atom of the cyclic amide group is optionally substituted by a C1-C6 alkyl group (preferably a C1-C5 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group).

[0034] In certain embodiments of the present application, the L and G are each independently selected from C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), or L, G and the N atom to which they are attached together form a 5-7 membered (preferably 5-6 membered) saturated aliphatic heterocyclic ring containing 1-3 heteroatoms (preferably 1-2 heteroatoms), and the heteroatoms are independently N, O or S (preferably N). In some preferred embodiments, the L and G are each independently selected from C1-C5 alkyl (preferably C1-C4 alkyl, or C1-C3 alkyl), or L, G and the N atom to which they are attached together form a 5-6 membered saturated aliphatic heterocyclic ring containing 1-2 heteroatoms (for example, 1 heteroatom), and the heteroatom is N, and the saturated aliphatic heterocyclic ring is optionally substituted with halogen (for example, fluorine, chlorine, bromine, iodine) or C1-C6 alkyl (preferably, the saturated aliphatic heterocyclic ring is substituted with fluorine, chlorine, bromine or iodine).

[0035] In certain embodiments of the present application, L and G are optionally substituted with halogen (eg, fluorine, chlorine, bromine, iodine) or C1-C6 alkyl.

[0036] In certain embodiments of the present application, is a single bond or a double bond, and when When it is a double bond, X and Y are each independently selected from CR B or N; when When it is a single bond, X and Y are CR C R D , R B 、R C 、R D Each is independently selected from hydrogen, hydroxy, halogen, cyano, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 haloalkyl. In some preferred embodiments, Is a single bond, X, Y are CR C R D , the R C 、R D are independently selected from hydrogen, hydroxyl, or C1-C6 alkyl; preferably, the R C and R D In some preferred embodiments, is a double bond, X and Y are each independently selected from CR B or N, and at least one of X and Y is CR B , the R B is selected from hydrogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 haloalkyl, preferably, the R B Selected from hydrogen, C1~C6 alkyl (preferably C1~C5 alkyl, C1~C4 alkyl, or C1~C3 alkyl), C1~C6 haloalkyl (preferably C1~C5 haloalkyl, C1~C4 haloalkyl, or C1~C3 haloalkyl).

[0037] In certain embodiments of the present application, R A is selected from hydrogen, hydroxy, halogen (such as fluorine, chlorine, bromine, iodine), amino, cyano, C3-C8 cycloalkyl (such as C3-C7 cycloalkyl, C3-C6 cycloalkyl, C3-C5 cycloalkyl, or C3-C4 cycloalkyl), C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), C1-C6 alkoxy (such as C1-C5 alkoxy, C1-C4 alkoxy, or C1-C3 alkoxy), C1-C6 haloalkyl (preferably C1-C5 haloalkyl, C1-C4 haloalkyl, or C1-C3 haloalkyl). In some preferred embodiments, R ASelected from hydrogen, halogen (such as fluorine, chlorine, bromine, iodine), amino, cyano, C3~C6 cycloalkyl (such as C3~C5 cycloalkyl, or C3~C4 cycloalkyl), C1~C6 alkyl (preferably C1~C5 alkyl, C1~C4 alkyl, or C1~C3 alkyl), C1~C6 alkoxy (such as C1~C5 alkoxy, C1~C4 alkoxy, or C1~C3 alkoxy), C1~C6 haloalkyl (preferably C1~C5 haloalkyl, C1~C4 haloalkyl, or C1~C3 haloalkyl).

[0038] The present application also provides a compound represented by formula (II), a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug thereof:

[0039] Among them, R 1 , o is consistent with the above definition of this application, ring A is selected from aromatic ring, aromatic heterocycle, unsaturated aliphatic heterocycle,

[0040] Ring B is a 3- to 12-membered saturated aliphatic heterocyclic ring or a ring formed by combining a 3- to 12-membered saturated aliphatic heterocyclic ring and a benzene ring.

[0041] is a single bond or a double bond, and when When it is a double bond, X and Y are each independently selected from CR B or N; when When it is a single bond, X and Y are CR C R D ,

[0042] R A 、R B 、R C 、R D Each is independently selected from hydrogen, hydroxyl, halogen, amino, cyano, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl,

[0043] The aromatic heterocycle, saturated aliphatic heterocycle, unsaturated aliphatic heterocycle, and aliphatic heterocycle each independently contain 1 to 3 heteroatoms, the heteroatoms are independently selected from N, O, and S, and ring B contains at least 1 nitrogen atom;

[0044] The ring B is optionally substituted by one or more groups independently selected from deuterium, tritium, nitro, hydroxyl, -NH2, thiol, halogen, cyano, ester, carboxyl, amide, =O, =NH, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, and 5-10 membered heteroaryl.

[0045] In certain embodiments of the present application, o is 0 or 2. When o is 2, any two R 1Together with the atoms of the ring A to which it is connected, it forms a 3-8 membered (e.g., 5-7 membered or 5-6 membered) aliphatic heterocyclic group. In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 5-7 membered (preferably 5-6 membered) aliphatic heterocyclic group containing 1-3 heteroatoms (preferably 1-2 heteroatoms, or 1 heteroatom), wherein the heteroatoms are independently N, O or S (preferably N). In some preferred embodiments, the R 1 Optionally substituted by one or two independently selected from =O, C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl). In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a saturated or unsaturated 5-6 membered cyclic amide group, which is unsubstituted or further substituted by a C1-C6 alkyl group (preferably a C1-C5 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group). In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a saturated or unsaturated 5- to 6-membered cyclic amide group, wherein the nitrogen atom of the cyclic amide group is optionally substituted by a C1-C6 alkyl group (preferably a C1-C5 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group).

[0046] Furthermore, the ring B is preferably a monocyclic, fused or spirocyclic ring. Preferably, the ring B is a 5-7 membered (preferably 5-6 membered) saturated alicyclic heterocyclic ring containing 1-3 heteroatoms (preferably 1-2 heteroatoms), wherein the heteroatoms are independently N, O or S (preferably N). Further preferably, the ring B is a 5-6 membered saturated alicyclic heterocyclic ring containing 1-2 heteroatoms (e.g., 1 heteroatom), wherein the heteroatom is N, and the ring B is optionally substituted with halogen (e.g., fluorine, chlorine, bromine, iodine) or C1-C6 alkyl (preferably, the ring B is optionally substituted with fluorine, chlorine, bromine or iodine).

[0047] In certain embodiments of the present application, the aforementioned ring B is selected from

[0048] Wherein Z is selected from covalent bond, O, S, NH, (CH2) n , SO2;

[0049] m is selected from 0, 1, 2, 3; R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, halogen, amine, ester, aldehyde, carboxyl, amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl; and n is selected from 1, 2, or 3.

[0050] Further, in certain embodiments, the ring B is selected from (For example Preferred ), where m, R 2 The definition is consistent with the previous definition in this application;

[0051] Further, in certain specific embodiments of the present application, the R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, fluorine, chlorine, bromine, amino, ester, aldehyde, carboxyl, amide, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclobutyl, cyclopropyl, phenyl, pyridyl. Preferably, the R 2 Each is independently selected from fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, preferably fluorine, chlorine or bromine.

[0052] In certain embodiments of the present application, the Is a single bond, and X, Y are CR C R D , the R C 、R D is selected from hydrogen, hydroxy, cyano, halogen, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl. Or preferably, the R C 、R D Each independently selected from hydrogen, hydroxyl, or C1-C6 alkyl; for example, the R C and R D For hydrogen.

[0053] In certain embodiments of the present application, the is a double bond, and at least one of X and Y is selected from CR B In certain preferred embodiments of the present application, the is a double bond, and the Y is selected from N, and the X is selected from CR B In certain preferred embodiments of the present application, the is a double bond, and the X is selected from N, and the Y is selected from CR B In certain preferred embodiments of the present application, the is a double bond, and X and Y are both selected from CR B ;

[0054] Among them, the R Bis selected from hydrogen, hydroxyl, cyano, halogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; preferably, the R B is selected from hydrogen, hydroxy, cyano, halogen, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl. Or preferably, the R B is selected from hydrogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 haloalkyl; more preferably, the R B Selected from hydrogen, C1~C6 alkyl (preferably C1~C5 alkyl, C1~C4 alkyl, or C1~C3 alkyl), C1~C6 haloalkyl (preferably C1~C5 haloalkyl, C1~C4 haloalkyl, or C1~C3 haloalkyl).

[0055] In certain embodiments of the present application, R A is selected from hydrogen, hydroxy, halogen (e.g., fluorine, chlorine, bromine, iodine), amino, cyano, C3-C8 cycloalkyl (e.g., C3-C7 cycloalkyl, C3-C6 cycloalkyl, C3-C5 cycloalkyl, or C3-C4 cycloalkyl), C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), C1-C6 alkoxy (e.g., C1-C5 alkoxy, C1-C4 alkoxy, or C1-C3 alkoxy), C1-C6 haloalkyl (preferably C1-C5 haloalkyl, C1-C4 haloalkyl, or C1-C3 haloalkyl). Preferably; R A is selected from hydrogen, halogen (such as fluorine, chlorine, bromine, iodine), amino, cyano, C3-C6 cycloalkyl (such as C3-C5 cycloalkyl, or C3-C4 cycloalkyl), C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), C1-C6 alkoxy (such as C1-C5 alkoxy, C1-C4 alkoxy, or C1-C3 alkoxy), C1-C6 haloalkyl (preferably C1-C5 haloalkyl, C1-C4 haloalkyl, or C1-C3 haloalkyl). Or in certain embodiments of the present application, the R A Selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, iodine, -NH2, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

[0056] In certain embodiments of the present application, Ring A is selected from a 6-10 membered aromatic ring, a 5-10 membered aromatic heterocycle, or a 6-8 membered unsaturated alicyclic ring; preferably, the aromatic ring or aromatic heterocycle is a monocyclic or fused ring, the unsaturated alicyclic ring is a monocyclic ring, and the aromatic heterocycle and unsaturated alicyclic ring each independently contain 1-3 heteroatoms, each independently selected from N, O, and S. Preferably, Ring A is selected from a 6-10 membered aromatic ring or a 5-10 membered aromatic heterocycle containing 1-3 heteroatoms (preferably 1-2 heteroatoms), each independently selected from N, O, and S. More preferably, Ring A is a benzene ring or a 5-10 membered aromatic heterocycle containing 1-2 heteroatoms, each independently selected from N or S.

[0057] In an embodiment of the present application, the present application also provides a compound as shown in formula (III), its stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof,

[0058] Among them, R 1 , o is consistent with the above definition of this application, ring A is selected from aromatic ring, aromatic heterocycle, unsaturated aliphatic heterocycle, Z is selected from covalent bond, S, NH, CH2, (CH2)2 or (CH2)3, m is selected from 0, 1, 2, R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, halogen, amine, ester, aldehyde, carboxyl, amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl, is a single bond or a double bond, and when When it is a double bond, X and Y are each independently selected from CR B or N, when When it is a single bond, X and Y are CR C R D , R A 、R B 、R C 、R D Each is independently selected from hydrogen, hydroxyl, halogen, amino, cyano, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl;

[0059] Preferably, the R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, fluorine, chlorine, bromine, amino, ester, aldehyde, carboxyl, amide, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclobutyl, cyclopropyl, phenyl, pyridyl. Preferably, the R 2Each is independently selected from fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, preferably fluorine, chlorine or bromine.

[0060] Further, in the embodiments of the present application, the m may be 0 or 1;

[0061] Further, in an embodiment of the present application, Z is a covalent bond or CH2; in certain embodiments of the present application, Z is CH2.

[0062] In certain embodiments of the present application, the Is a single bond, and X, Y are CR C R D , the R C 、R D is selected from hydrogen, hydroxy, cyano, halogen, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl. Or preferably, the R C 、R D Each independently selected from hydrogen, hydroxyl, or C1-C6 alkyl; for example, the R C and R D For hydrogen.

[0063] In certain embodiments of the present application, the is a double bond, and at least one of X and Y is selected from CR B In certain preferred embodiments of the present application, the is a double bond, and the Y is selected from N, and the X is selected from CR B In certain preferred embodiments of the present application, the is a double bond, and the X is selected from N, and the Y is selected from CR B In certain preferred embodiments of the present application, the is a double bond, and X and Y are both selected from CR B ;

[0064] Among them, the R B is selected from hydrogen, hydroxyl, cyano, halogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; preferably, the R B is selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl. Or preferably, the R B is selected from hydrogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 haloalkyl; more preferably, the R BSelected from hydrogen, C1~C6 alkyl (preferably C1~C5 alkyl, C1~C4 alkyl, or C1~C3 alkyl), C1~C6 haloalkyl (preferably C1~C5 haloalkyl, C1~C4 haloalkyl, or C1~C3 haloalkyl).

[0065] In certain embodiments of the present application, R A is selected from hydrogen, hydroxy, halogen (e.g., fluorine, chlorine, bromine, iodine), amino, cyano, C3-C8 cycloalkyl (e.g., C3-C7 cycloalkyl, C3-C6 cycloalkyl, C3-C5 cycloalkyl, or C3-C4 cycloalkyl), C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), C1-C6 alkoxy (e.g., C1-C5 alkoxy, C1-C4 alkoxy, or C1-C3 alkoxy), C1-C6 haloalkyl (preferably C1-C5 haloalkyl, C1-C4 haloalkyl, or C1-C3 haloalkyl). Preferably, R A is selected from hydrogen, halogen (such as fluorine, chlorine, bromine, iodine), amino, cyano, C3-C6 cycloalkyl (such as C3-C5 cycloalkyl, or C3-C4 cycloalkyl), C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), C1-C6 alkoxy (such as C1-C5 alkoxy, C1-C4 alkoxy, or C1-C3 alkoxy), C1-C6 haloalkyl (preferably C1-C5 haloalkyl, C1-C4 haloalkyl, or C1-C3 haloalkyl). Or in the embodiment of the present application, the R A Selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, iodine, -NH2, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

[0066] In an embodiment of the present application, the ring A described in the present application is selected from a 6-10 membered aromatic ring, a 5-10 membered aromatic heterocycle, or a 6-8 membered unsaturated alicyclic ring. Furthermore, the aromatic ring or aromatic heterocycle is preferably a monocyclic or cyclic ring, the unsaturated alicyclic ring is preferably a monocyclic ring, and the aromatic heterocycle and unsaturated alicyclic ring each independently contain 1 to 3 heteroatoms, and the heteroatoms are independently selected from N, O, and S. Preferably, the ring A is selected from a 6-10 membered aromatic ring or a 5-10 membered aromatic heterocycle containing 1 to 3 heteroatoms (preferably 1 to 2 heteroatoms), and the heteroatoms are independently selected from N, O, and S. More preferably, the ring A is a benzene ring or a 5-10 membered aromatic heterocycle containing 1 to 2 heteroatoms, and the heteroatoms are independently N or S.

[0067] In certain embodiments of the present application, the ring A is selected from

[0068] In certain embodiments of the present application, the ring A is selected from The ring A is more preferably selected from The ring A is further selected from

[0069] In certain embodiments of the present application, the R 1 R is independently selected from deuterium, tritium, nitro, hydroxyl, sulfhydryl, halogen, cyano, =0, imino, amine, ester, aldehyde, carboxyl, amide, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methyl, ethyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dioxhexyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentyl, tert-pentoxy, n-hexyl, or any two R 1 The atoms of the ring A to which it is connected together form a dioxanyl, dioxolane, dioxinyl, dioxolenyl, dihydropyridinyl, pyrrolinyl, wherein R 1 Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, -NH2, thiol, halogen, cyano, ester, carboxyl, amide, =O, =NH, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

[0070] In certain embodiments of the present application, the R 1 R is independently selected from deuterium, tritium, nitro, hydroxyl, sulfhydryl, halogen, cyano, =0, imino, amine, ester, aldehyde, carboxyl, amide, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methyl, ethyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dioxhexyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentyl, tert-pentoxy, n-hexyl, or any two R 1 The atoms of the ring A to which it is connected together form a dioxanyl group or a dioxolane group, wherein R 1Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, -NH2, thiol, halogen, cyano, ester, carboxyl, amide, =O, =NH, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

[0071] In certain specific embodiments of the present application, the R 1 Each is independently preferably selected from deuterium, tritium, nitro, hydroxyl, mercapto, cyano, =O, =NH, -NH2, -N(CH3)2, -NHCH3, =NCH3, ester, aldehyde, carboxyl, amide, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methyl, ethyl, isopropyl, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, morpholinyl, piperidinyl, N-methylpiperazinyl, p-methylpiperidinyl, piperazinyl, methoxy, ethoxy, isopropoxy, halogen; or two R 1 The atoms of the ring A to which it is connected together form 1,4-dioxanyl, 1,3-dioxanyl, 1,3-dioxolane, 1,4-dioxinyl, 1,3-dioxinyl, 1,3-dioxolanyl, N-methyl-2-pyridone, N-methyl-3-pyrrolidine-2-one; preferably, R described in this application 1 Each R is independently preferably selected from deuterium, tritium, nitro, hydroxyl, mercapto, cyano, =O, =NH, -NH2, -N(CH3)2, -NHCH3, =NCH3, ester, aldehyde, carboxyl, amide, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methyl, ethyl, isopropyl, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, morpholinyl, piperidinyl, N-methylpiperazinyl, p-methylpiperidinyl, piperazinyl, methoxy, ethoxy, isopropoxy, halogen; or two R 1 Together with the atoms of the ring A to which it is connected, it forms a 1,4-dioxanyl group, a 1,3-dioxanyl group, or a 1,3-dioxolane group.

[0072] In certain embodiments of the present application, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 3-8 membered (e.g., 5-7 membered or 5-6 membered) aliphatic heterocyclic group. In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 5-7 membered (preferably 5-6 membered) aliphatic heterocyclic group containing 1-3 heteroatoms (preferably 1-2 heteroatoms, or 1 heteroatom), wherein the heteroatoms are independently N, O or S (preferably N). In some preferred embodiments, the R 1Optionally substituted by one or two independently selected from =O, C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl). In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a saturated or unsaturated 5-6 membered cyclic amide group, which is unsubstituted or further substituted by a C1-C6 alkyl group (preferably a C1-C5 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group). In some preferred embodiments, o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a saturated or unsaturated 5- to 6-membered cyclic amide group, wherein the nitrogen atom of the cyclic amide group is optionally substituted by a C1-C6 alkyl group (preferably a C1-C5 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group).

[0073] In some preferred embodiments, any two R 1 Together with the atoms of the ring A to which it is connected, it forms N-methyl-2-pyridone, N-methyl-5,6-dihydro-pyridin-2-one N-methyl-3,4-dihydro-pyridin-2-one Pyridin-2-one N-methyl-3-pyrrolidine-2-one, pyrrol-2-one 3-Pyrrolidine-2-one

[0074] In certain preferred embodiments, the two R 1 The group structure formed by the atoms of the ring A to which it is connected is as follows: The structure of 1,4-dioxane is The 1,3-dioxolane structure is The 1,4-dioxinyl structure can be The 1,3-dioxinyl structure is The structure of 1,3-dioxolyl is The N-methyl-2-pyridone structure can be The structure of N-methyl-3-pyrrolidine-2-one is

[0075] In some embodiments of the present application, in the compound represented by formula (III), stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts thereof, or solvates (e.g., hydrates) thereof, or prodrugs thereof, the ring A is a benzene ring, a naphthalene ring, or a 5-10 membered aromatic heterocycle containing 1-2 heteroatoms, wherein the heteroatoms are independently N or S (e.g., the ring A is selected from ); o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, a saturated or unsaturated 5- to 6-membered cyclic amide group is formed, wherein the nitrogen atom of the cyclic amide group is optionally substituted by a C1-C6 alkyl group (preferably a C1-C5 alkyl group, a C1-C4 alkyl group, or a C1-C3 alkyl group) (for example, any two R 1 Together with the atoms of the ring A to which it is connected, it forms N-methyl-2-pyridone, N-methyl-5,6-dihydro-pyridone, N-methyl-3,4-dihydro-pyridone, pyridone, N-methyl-3-pyrrolidine-2-one, pyrrole-2-one, 3-pyrrolidine-2-one); the Is a single bond, and X, Y are CR C R D , the R C 、R D Each independently selected from hydrogen, hydroxyl, or C1-C6 alkyl (for example, the R C and R D is hydrogen), or is a double bond, and at least one of X and Y is selected from CR B , the R B is selected from hydrogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 haloalkyl (for example, the R B is selected from hydrogen, C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), C1-C6 haloalkyl (preferably C1-C5 haloalkyl, C1-C4 haloalkyl, or C1-C3 haloalkyl); R A is selected from hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), amino, cyano, C3-C6 cycloalkyl (e.g., C3-C5 cycloalkyl, or C3-C4 cycloalkyl), C1-C6 alkyl (preferably C1-C5 alkyl, C1-C4 alkyl, or C1-C3 alkyl), C1-C6 alkoxy (e.g., C1-C5 alkoxy, C1-C4 alkoxy, or C1-C3 alkoxy), C1-C6 haloalkyl (preferably C1-C5 haloalkyl, C1-C4 haloalkyl, or C1-C3 haloalkyl), such as R A is selected from hydrogen, fluorine, chlorine, bromine, iodine, -NH2, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl; Z is a covalent bond or CH2 (preferably Z is CH2); m is 0, 1 or 2; R 2 Each independently selected from fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl (preferably the R 2 are each independently fluoro, chloro or bromo).

[0076] In some specific embodiments of the present application, the compound of the present application is as follows, its tautomer or mixture form, or its pharmaceutically acceptable salt, or its solvate, or its prodrug:

[0077] Another aspect of the present application is to provide a pharmaceutical composition comprising at least one of the aforementioned compounds, stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, and at least one pharmaceutically acceptable excipient.

[0078] Another aspect of the present application is to provide a compound, or a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a pharmaceutical composition for the preparation of a drug. Wherein, the drug is a 15-PGDH inhibitor, which can be used to treat diseases associated with increased levels of unwanted 15-PGDH activity. Alternatively, the present application provides a compound, or a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a pharmaceutical composition for use as a drug. Alternatively, the present application provides a method for treating or preventing a 15-PGDH-related disease, comprising administering the compound, or a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt, or a solvate, or a prodrug, or a pharmaceutical composition to a subject in need. The 15-PGDH-related disease herein refers to a disease or complication thereof that achieves clinically beneficial therapeutic effects such as alleviation, improvement, cessation of progression, alleviation, or no longer worsening by inhibiting 15-PGDH activity.

[0079] In certain specific embodiments, the medicament or method is used to treat or prevent fibrosis, oral ulcers, gum disease, colitis, ulcerative colitis, gastroduodenal ulcers, inflammatory diseases, vascular insufficiency, Raynaud's disease, Buerger's disease, neuropathy, pulmonary hypertension, cardiovascular and renal diseases, cardiovascular diseases, trauma, skin injuries, autoimmune diseases, graft-versus-host disease, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, or to promote hair growth, pigmentation, tissue repair, tissue regeneration, implantation in stem cell transplantation, bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, muscle regeneration and cervical ripening, or to enhance resistance to the toxicity of chemotherapy and the toxicity of immunosuppressants.

[0080] definition

[0081] Unless otherwise stated, the following terms used in the specification and claims have the following meanings. A particular term should not be considered ambiguous or unclear if it is not specifically defined, but should be understood according to its ordinary meaning in the art.

[0082] "Chained hydrocarbon group" refers to a group of aliphatic groups that are connected in a chain and contain only carbon and hydrogen atoms. The hydrocarbon group can be a saturated hydrocarbon group or an unsaturated hydrocarbon group; the chain can be straight chain or branched chain. 10 A chain hydrocarbon group refers to a straight-chain hydrocarbon group or a branched hydrocarbon group consisting of 1 to 10 carbon atoms (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or a range consisting of any two of the foregoing values), and the hydrocarbon group may be a saturated hydrocarbon group or an unsaturated hydrocarbon group.

[0083] "Alkyl" refers to a saturated aliphatic chain hydrocarbon group. The alkyl portion may be a straight-chain alkyl group or a branched alkyl group. As used herein, a C1-C6 alkyl group refers to a straight-chain alkyl group or a branched-chain alkyl group consisting of 1 to 6 carbon atoms (e.g., 1, 2, 3, 4, 5, or 6, or a range consisting of any two of the foregoing values). Typical alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, and the like.

[0084] "Alkoxy" refers to an -O-alkyl group; as used herein, a C1-C6 alkoxy group refers to a straight-chain or branched alkoxy group consisting of 1 to 6 carbon atoms (e.g., 1, 2, 3, 4, 5, or 6, or a range consisting of any two of the foregoing values). Typical alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentoxy, tert-pentoxy, n-hexoxy, and the like.

[0085] "Ring" refers to any cyclic covalently closed structure, including, for example, a carbocycle (e.g., an aromatic ring or an alicyclic ring) or a heterocycle (e.g., an aromatic heterocycle or an alicyclic heterocycle). A carbocycle refers to a ring consisting solely of carbon atoms, and a heterocycle refers to a closed structure formed by covalent bonding of carbon atoms and heteroatoms. A ring may be a monocyclic, bicyclic, tricyclic, or polycyclic ring. When a ring is bicyclic, tricyclic, or polycyclic, the relationship between the rings may include a fused ring, a spirocyclic ring, or a bridged ring. For example, a bicyclic ring may include a spirocyclic ring, a fused ring, or a bridged ring; a tricyclic ring may include three spirocyclic rings, three fused rings, or a spirocyclic ring combined with a monocyclic ring.

[0086] In the present application, "combined" refers to a structure formed by sharing two adjacent ring atoms between rings. For example, a combined ring refers to a cyclic structure formed by sharing two adjacent ring atoms between two monocyclic rings.

[0087] "Heteroatom" refers to any atom other than a carbon atom that can be covalently bonded to a carbon atom. Common heteroatoms include, but are not limited to, O, S, N, P, Si, etc.

[0088] "Member" refers to the number of atoms that make up the ring. Typical 5-membered rings include, but are not limited to, cyclopentane, pyrrole, imidazole, thiazole, furan, and thiophene; typical 6-membered rings include, but are not limited to, cyclohexane, pyridine, pyran, pyrazine, thiopyran, pyridazine, pyrimidine, and benzene.

[0089] "Alicyclic ring" or "alicyclic group" refers to a saturated or partially unsaturated carbon ring. A saturated carbon ring may be referred to as a saturated alicyclic ring, and a partially unsaturated carbon ring may be referred to as an unsaturated alicyclic ring. An alicyclic ring may be composed of 3 to 10 atoms and may be monocyclic or polycyclic. For example, the C3 to C8 alicyclic group used in this application refers to an alicyclic group composed of 3 to 8 backbone atoms. Typical alicyclic structures include, but are not limited to: wait.

[0090] "Aliphatic heterocycle" or "aliphatic heterocyclic group" refers to a non-aromatic cyclic group formed by replacing carbon atoms in an aliphatic ring with one or more heteroatoms. Aliphatic heterocycles or aliphatic heterocyclic groups can include saturated aliphatic heterocycles and unsaturated aliphatic heterocycles. For example, a 3- to 8-membered aliphatic heterocyclic group as used herein refers to a non-aromatic cyclic group composed of 3-8 backbone atoms and containing one or more heteroatoms, and can be a saturated aliphatic heterocyclic group or an unsaturated aliphatic heterocyclic group.

[0091] "Saturated heterocyclic ring" or "saturated heterocyclic group" means that the carbon atoms constituting the ring backbone of the heterocyclic ring are all saturated. For example, as used in this application, a 3-12-membered saturated heterocyclic ring refers to a non-aromatic cyclic group formed by 3-12 atoms constituting the ring backbone, wherein the atoms constituting the ring backbone are composed of saturated carbon atoms and heteroatoms. Typical saturated heterocyclic rings include, but are not limited to: wait.

[0092] As used in this application, "a ring formed by combining a 3- to 12-membered saturated aliphatic heterocycle and a benzene ring" refers to a saturated aliphatic heterocycle composed of 3 to 12 atoms, which is combined with a benzene ring to form a ring structure. For example wait.

[0093] In this application, "unsaturated heterocyclic ring" refers to a ring containing unsaturated carbon atoms in its backbone. As used herein, a 6- to 8-membered unsaturated heterocyclic ring refers to a non-aromatic cyclic group consisting of 6-8 backbone atoms, wherein the atoms constituting the ring backbone include saturated carbon atoms, unsaturated carbon atoms, and heteroatoms. Typical unsaturated heterocyclic rings include, but are not limited to: wait.

[0094] "Cycloalkyl" refers to a saturated aliphatic carbocyclic group, also known as a saturated alicyclic ring. Cycloalkyl groups can be monocyclic, spirocyclic, fused, or bridged. As used herein, a C3-C8 cycloalkyl group refers to a cyclic alkyl group composed of 3 to 8 carbon atoms. Typical cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2,1,1]hexyl, and cycloheptyl.

[0095] "Aromatic ring" or "aryl" refers to a fully unsaturated carbon ring whose planar ring has a delocalized π electron system and contains 4n+2 π electrons, where n is an integer. An aromatic ring can be composed of six, eight, ten or more carbon atoms, and can be a monocyclic or polycyclic ring. Common aromatic rings include, but are not limited to, benzene rings, naphthalene rings, phenanthrene rings, anthracene rings, tetraphenyl rings, pyrene rings, pentaphenyl rings, and the like. As used in this application, a 6- to 10-membered aromatic ring or 6- to 10-membered aryl group refers to an aromatic ring group composed of 6 to 10 backbone carbon atoms.

[0096] "Aromatic heterocycle" or "heteroaryl" refers to an aromatic ring structure formed by replacing one or more heteroatoms with carbon atoms in the aromatic ring. Typical aromatic heterocycles or heteroaryl groups include but are not limited to: wait.

[0097] The 5- to 10-membered aromatic heterocycle or 5- to 10-membered heteroaryl group used in the present application refers to an aromatic ring group containing hetero atoms and composed of 5 to 10 backbone atoms.

[0098] "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.

[0099] "Haloalkyl" refers to an alkyl group in which at least one hydrogen is replaced by a halogen atom. The C1-C6 haloalkyl group used in this application refers to a straight-chain or branched alkyl group consisting of 1 to 6 carbon atoms, in which at least one hydrogen is arbitrarily replaced by a halogen atom.

[0100] "Amine" or "amine" refers to a group having -NR U R V The chemical structure of U R V Each is independently selected from hydrogen, deuterium, tritium, alkyl, and cycloalkyl.

[0101] "Iminyl" or "imine" refers to a group having ═NR W The chemical structure of W Selected from hydrogen, deuterium, tritium, alkyl, cycloalkyl.

[0102] "Amide" or "amido" refers to a group having -C(O)NR X RY or -NR X C(O)R Y The chemical structure of X 、R Y Each is independently selected from hydrogen, deuterium, tritium, alkyl, cycloalkyl, common amide groups include but are not limited to -CONH2, -CONHCH3, -CON(CH3)2, -NHCOH, -NHCOCH3, -N(CH3)COCH3.

[0103] An "ester group" is a group having the formula -COOR 0 The chemical structure of 0 Selected from alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl.

[0104] "Substitution" refers to that one or more hydrogen atoms in a group are replaced by a corresponding number of substituents independently of one another. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without making too much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (such as olefinic) bond. Each and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, hydroxyl, alkoxy, alkylthio, aryloxy, nitro, acyl, halogen, haloalkyl, amino, etc. When two or more "substitutions" occur, the substituents can form a cyclic group together with the substituted atom. For example, two R 1 The 1,4-dioxane structure formed by the atoms of the ring A to which it is connected is The 1,3-dioxolane structure is The 1,4-dioxinyl structure can be The 1,3-dioxinyl structure is The structure of 1,3-dioxolyl is The N-methyl-2-pyridone structure can be The structure of N-methyl-3-pyrrolidine-2-one is

[0105] "Inhibitor" refers to a substance that reduces the activity of an enzyme.

[0106] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "optionally substituted" includes both substituted and unsubstituted. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.

[0107] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.

[0108] "Pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0109] As the pharmaceutically acceptable salt, for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids and the like can be mentioned.

[0110] "Tautomers" or "tautomeric forms" refer to structural isomers of different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer is the imidazole moiety, where the proton can migrate between two ring nitrogens. Valence tautomers include interconversions via reorganization of some of the bonding electrons. Non-limiting examples of tautomers include, but are not limited to,

[0111] "Stereoisomers" refer to isomers that differ in the way the atoms in a molecule are arranged in space.

[0112] "Enantiomers" refer to compounds with the same molecular formula and functional groups, which exhibit isomerism due to different configurations of atoms in space. At the same time, the compounds form non-superimposable stereoisomers that are mirror images of each other.

[0113] "Diastereoisomers" refer to compounds with the same molecular formula and functional groups, which are stereoisomers caused by different spatial configurations of atoms. At the same time, the compounds are not stereoisomers that are in a mirror-image relationship with each other.

[0114] Unless otherwise indicated, the terms "comprise, comprise, and comprising" or their equivalents (contain, contains, containing, include, includes, including) used herein are open-ended expressions and mean that in addition to the listed elements, components, and steps, other unspecified elements, components, and steps may also be included.

[0115] Unless otherwise indicated, all numbers used herein expressing amounts of ingredients, measurements, or reaction conditions are to be understood as modified in all instances by the term "about." When used in conjunction with a percentage, the term "about" can mean, for example, ±1%, preferably ±0.5%, and more preferably ±0.1%.

[0116] Unless the context clearly indicates otherwise, singular terms herein include plural referents and vice versa. Similarly, the word "or" herein is intended to include "and" unless the context clearly indicates otherwise.

[0117] Obviously, based on the above content of this application, in accordance with the common technical knowledge and means in this field, without departing from the above basic technical ideas of this application, various other forms of modifications, replacements or changes can be made.

[0118] The abbreviations in this application have the following meanings: DETAILED DESCRIPTION

[0119] The following examples illustrate the synthesis methods of the compounds and intermediates of this application. The following examples are merely examples of this application and should not be construed as limiting the scope of this application. Unless otherwise specified, the raw materials and reagents involved in this application can be obtained through commercial channels, and the specific source of the channel does not affect the implementation of the technical solution of this application.

[0120] Preparation Example 1: Preparation of sodium 2-oxo-2-(piperidin-1-yl)ethane-1-thiolate

[0121] Step 1: Preparation of S-(2-oxo-2-(piperidin-1-yl)ethyl)thioethyl ester

[0122] 2-Chloro-1-piperidin-1-ylethanone (10.0 g) was dissolved in acetonitrile (100 mL), and sodium thioacetate (12.1 g) was added. The mixture was stirred at room temperature overnight. LCMS confirmed the reaction was complete, and water was added to quench the reaction. The acetonitrile was removed by concentration under reduced pressure, and the mixture was extracted three times with ethyl acetate (100 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 10.5 g of the title compound. MS (ESI) m / z (M+H) + =202.1.

[0123] Step 2: Preparation of sodium 2-oxo-2-(piperidin-1-yl)ethane-1-thiolate

[0124] S-(2-oxo-2-(piperidin-1-yl)ethyl)thioethyl ester (10.5 g) was dissolved in a mixture of ethanol and water (EtOH:H2O = 2:1 (v / v)). Sodium hydroxide (6.3 g) was added and stirred at room temperature for 2 hours. After completion of the reaction as monitored by LCMS, the reaction was stopped to obtain a solution of the target compound in ethanol and water at a concentration of approximately 1 mmol / mL. This solution was used without further purification. MS (ESI) m / z (M+H) + =160.1.

[0125] Preparation Example 2: Preparation of ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0126] Step 1: Preparation of ethyl 2-cyano-3,3-bis(methylthio)acrylate

[0127] NaH (5.3 g) was dissolved in tetrahydrofuran (100 mL), and ethyl cyanoacetate (10.0 g) was added under nitrogen protection. Then, carbon disulfide (5.3 mL) was slowly added dropwise in a dry ice bath and cooled to -78°C. After the addition was complete, the mixture was stirred and reacted at -78°C for 1 hour. When the system turned light yellow, iodomethane (13.7 mL) was slowly added dropwise. After the addition was complete, the mixture was stirred and reacted at -78°C for 1 hour, and then the temperature was slowly raised to 0°C and reacted for 1 hour. LCMS monitored the reaction completion, and the reaction was quenched by adding water. The tetrahydrofuran was removed by concentration under reduced pressure, and the residue was poured into ice water. A yellow solid was precipitated by continuous stirring. The product was filtered, washed with water, and dried to obtain 13 g of the title compound. MS (ESI) m / z (M+H) + =218.1.

[0128] Step 2: Preparation of 4-hydroxy-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile

[0129] Ethyl 2-cyano-3,3-bis(methylthio)acrylate (13 g), benzamidine hydrochloride (7.9 g), and potassium carbonate (24.8 g) were dissolved in a mixture of acetonitrile and water (ACN:H2O = 4:1 (v / v)) and stirred at room temperature for 1 hour. The reaction was complete as monitored by LCMS. The organic solvent was removed by concentration under reduced pressure to precipitate a solid, which was filtered, washed with water, and dried under vacuum to yield 16 g of the title compound. MS (ESI) m / z (M+H) + =244.1.

[0130] Step 3: Preparation of 4-chloro-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile

[0131] Dissolve the crude 4-hydroxy-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile (16 g) in phosphorus oxychloride (100 mL), heat to 100°C, and stir for 2 hours. LCMS monitoring confirmed the completion of the reaction. The phosphorus oxychloride was removed by concentration under reduced pressure, and the residue was poured into ice water. The solution was adjusted to a weak base with saturated NaHCO₃ solution and extracted three times with ethyl acetate (100 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 8 g of the title compound. MS (ESI) m / z (M+H) + =262.1.

[0132] Step 4: Preparation of ethyl 5-amino-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0133] Sodium hydride (2.4 g) was dissolved in tetrahydrofuran (50 mL). Under nitrogen protection, ethyl mercaptoacetate (1.7 mL) was slowly added dropwise in an ice-salt bath. After completion of the addition, the reaction was allowed to react for 0.5 hours. 4-Chloro-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile (2 g) was then slowly added and the reaction was continued with stirring in an ice-salt bath for 1 hour. LCMS monitored the reaction completion. Saturated ammonium chloride solution was added to quench the reaction. The tetrahydrofuran was removed by concentration under reduced pressure. The residue was extracted three times with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 2.3 g of the title compound. MS (ESI) m / z (M+H) + =346.1.

[0134] Step 5: Preparation of ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0135] Ethyl 5-amino-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (2.0 g) was added to acetonitrile (50 mL), followed by cuprous iodide (2.2 g). The temperature was raised to 60°C, and tert-butyl nitrite (1.2 g) was added dropwise. After addition, the mixture was stirred at 60°C for 2 hours. The reaction was stopped upon disappearance of the starting material as monitored by LCMS. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 1.0 g of the title compound. MS (ESI) m / z (M+H) + =457.1.

[0136] Preparation Example 3: Preparation of ethyl 4-(methylthio)-2-phenyl-5-(trifluoromethyl)thieno[2,3-d]pyrimidine-6-carboxylate

[0137] Ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (0.3 g) was added to N,N-dimethylformamide (5 mL), followed by cuprous iodide (30 mg) and methyl fluorosulfonyldifluoroacetate (0.4 g). The atmosphere was purged with nitrogen three times, then the temperature was raised to 90°C and stirred for 2 hours. LCMS monitored the reaction to be complete. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 120 mg of the title compound. MS (ESI) m / z (M+H) + =399.1.

[0138] Preparation Example 4: Preparation of ethyl 5-cyclopropyl-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0139] Ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (300 mg) was dissolved in a mixture of dioxane and water (Dioxane:H2O = 4:1 (v / v)). Potassium carbonate (182 mg), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (48 mg), and cyclopropylboronic acid (100 mg) were added. The atmosphere was purged with nitrogen three times, and the mixture was heated to 90°C and stirred for 2 hours. The reaction was complete as monitored by LCMS. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 160 mg of the title compound. MS (ESI) m / z (M+H) + =371.1.

[0140] Preparation Example 5: Preparation of ethyl 4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0141] Ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (0.3 g) was added to N,N-dimethylformamide (5 mL), followed by cuprous iodide (30 mg). The atmosphere was purged with nitrogen three times, then the temperature was raised to 90°C and stirred for 2 hours. LCMS monitored the reaction until complete. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to yield 100 mg of the title compound. MS (ESI) m / z (M+H) + =331.1.

[0142] Preparation Example 6: Preparation of ethyl 5-methyl-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0143] Dissolve ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (0.3 g) in dioxane (8 mL), then add cesium carbonate (40 mg), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (5 mg), and trimethylcyclotriboroxine (15 mg). Heat to 100°C and stir under nitrogen for 3 hours. The reaction was complete as monitored by LCMS, and the system was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 100 mg of the title compound. MS (ESI) m / z (M+H) + =345.1.

[0144] Example 1: Preparation of (9-amino-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(4-fluoropiperidin-1-yl)methanone

[0145] Step 1: Preparation of ethyl 2-cyano-3,3-bis(methylthio)acrylate

[0146] Sodium hydroxide (5.3 g) was dissolved in tetrahydrofuran (100 mL). Ethyl cyanoacetate (10.0 g, 88.41 mmol) was added under nitrogen protection. The mixture was then cooled to -78°C in a dry ice bath and carbon disulfide (5.3 mL) was slowly added dropwise. After the addition was complete, the mixture was stirred and reacted at -78°C for 1 hour. When the system turned light yellow, iodomethane (13.7 mL) was slowly added dropwise. After the addition was complete, the mixture was stirred and reacted at -78°C for 1 hour. The temperature was then slowly raised to 0°C and reacted for 1 hour. LCMS monitored the reaction completion, quenched the reaction with water, and concentrated under reduced pressure to remove tetrahydrofuran. The residue was poured into ice water and stirred continuously until a yellow solid precipitated. The product was filtered, washed with water, and dried to obtain 13 g of the title compound. MS (ESI) m / z (M+H) + =218.1.

[0147] Step 2: Preparation of 4-hydroxy-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile

[0148] Ethyl 2-cyano-3,3-bis(methylthio)acrylate (13 g), benzamidine hydrochloride (7.9 g), and potassium carbonate (24.8 g) were dissolved in a mixture of acetonitrile and water (ACN:H2O = 4:1 (v / v)) and stirred at room temperature for 1 hour. The reaction was complete as monitored by LCMS. The organic solvent was removed by concentration under reduced pressure to precipitate a solid, which was filtered, washed with water, and dried under vacuum to yield 16 g of the title compound. MS (ESI) m / z (M+H) + =244.1.

[0149] Step 3: Preparation of 4-chloro-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile

[0150] Dissolve the crude 4-hydroxy-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile (16 g) in phosphorus oxychloride (100 mL), heat to 100°C, and stir for 2 hours. After the disappearance of the starting material as monitored by LCMS, concentrate under reduced pressure to remove the phosphorus oxychloride. Pour the residue into ice water and adjust the solution to a weak base with saturated NaHCO3 solution. Extract three times with ethyl acetate (100 mL). Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The residue is purified by silica gel column chromatography to obtain 8 g of the title compound. MS (ESI) m / z (M+H) + =262.1.

[0151] Step 4: Preparation of ethyl 5-amino-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0152] Sodium hydride (2.4 g) was dissolved in tetrahydrofuran (50 mL). Under nitrogen protection, ethyl mercaptoacetate (1.7 mL) was slowly added dropwise in an ice-salt bath. After completion of the addition, the reaction was allowed to react for 0.5 hours. 4-Chloro-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile (2 g) was then slowly added and the reaction was continued with stirring in an ice-salt bath for 1 hour. LCMS monitored the reaction completion. Saturated ammonium chloride solution was added to quench the reaction. The tetrahydrofuran was removed by concentration under reduced pressure. The residue was extracted three times with ethyl acetate (50 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 2.3 g of the title compound. MS (ESI) m / z (M+H) + =346.1.

[0153] Step 5: Preparation of ethyl 5-amino-4-((2-hydroxyethyl)amino)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0154] Dissolve ethyl 5-amino-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (0.6 g) and 2-aminoethanol (0.4 g) in N,N-dimethylacetamide (5 mL) and microwave at 160°C for 2 hours. LCMS monitoring confirmed the completion of the reaction. Add 20 mL of water and extract three times with ethyl acetate (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.5 g of the title compound. MS (ESI) m / z (M+H) + =359.1.

[0155] Step 6: Preparation of 5-amino-4-((2-hydroxyethyl)amino)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid

[0156] Ethyl 5-amino-4-((2-hydroxyethyl)amino)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (100 mg) was dissolved in a mixture of ethanol and water (EtOH:H2O = 1:1 (v / v)). Lithium hydroxide monohydrate (67 mg) was added and the mixture was heated to 100°C and reacted for 0.5 hours. LCMS monitored the reaction completion, and the mixture was concentrated under reduced pressure to obtain 150 mg of the crude title compound, which was directly used in the next step without purification. MS (ESI) m / z (M+H) + =331.1.

[0157] Step 7: Preparation of (5-amino-4-((2-hydroxyethyl)amino)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(4-fluoropiperidin-1-yl)methanone

[0158] 5-Amino-4-((2-hydroxyethyl)amino)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid (100 mg), 4-fluoropiperidine hydrochloride (84 mg), and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (170 mg) were dissolved in tetrahydrofuran (5 mL). Triethylamine (0.5 mL) was added and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction completion. 20 mL of water was added and the mixture was extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 110 mg of the title compound. MS (ESI) m / z (M+H) + =416.1.

[0159] Step 8: Preparation of (9-amino-5-phenyl-2,3-dihydroimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(4-fluoropiperidin-1-yl)methanone (Compound 8)

[0160] (5-Amino-4-((2-hydroxyethyl)amino)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(4-fluoropiperidin-1-yl)methanone (100 mg), p-toluenesulfonyl chloride (92 mg), 4-dimethylaminopyridine (15 mg), and triethylamine (120 mg) were dissolved in dichloromethane (5 mL) and stirred at room temperature for 3 hours. The reaction was complete as monitored by LCMS, and water (10 mL) was added to terminate the reaction. The layers were separated, and the aqueous phase was extracted three times with ethyl acetate (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 50 mg of the title compound. MS (ESI) m / z (M+H) + =398.1.

[0161] 1 H NMR(400MHz,DMSO-d6)δ7.75-7.73(m,2H),7.65-7.46(m,3H),6.41(s,2H),4.99-4.83(m,1H), 4.04-3.99(m,2H),3.94-3.89(m,2H),3.68-3.62(m,2H),3.57-3.51(m,2H),1.99-1.87(m,2H),1.80-1.71(m,2H).

[0162] Step 9: Preparation of (9-amino-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(4-fluoropiperidin-1-yl)methanone

[0163] (9-Amino-5-phenyl-2,3-dihydroimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(4-fluoropiperidin-1-yl)methanone (50 mg) and 2,3-dichloro-5,6-dicyanobenzoquinone (75 mg) were dissolved in 1,4-dioxane (5 mL) and stirred at 70°C for 1 hour. The reaction was complete as monitored by LCMS. Water (10 mL) was added to terminate the reaction and the mixture was extracted three times with ethyl acetate (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLC to obtain the title compound. MS (ESI) m / z = 396.1 (M+H) + .

[0164] 1H NMR(400MHz,DMSO-d6)δ8.02(d,J=1.6Hz,1H),8.01-7.90(m,2H),7.77-7.58(m,4H),6.54(s,2H) ,5.01-4.88(m,1H),3.76-3.70(m,2H),3.67-3.61(m,2H),2.03-1.92(m,2H),1.83-1.76(m,2H).

[0165] Example 2: Preparation of (9-amino-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(4-fluoropiperidin-1-yl)methanone

[0166] Step 1: Preparation of ethyl 4,5-diamino-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate

[0167] Ethyl 5-amino-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (400 mg) was added to a 7M methanolic ammonia solution (5 mL) and heated at 100°C in a microwave oven for 6 hours. LCMS monitored the reaction completion, and the system was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 280 mg of the title compound. MS (ESI) m / z (M+H) + =315.2.

[0168] Step 2: Preparation of 4,5-diamino-2-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid

[0169] Ethyl 4,5-diamino-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (280 mg) was dissolved in a mixture of ethanol and water (EtOH:H2O = 1:1 (v / v), 20 mL). Lithium hydroxide monohydrate (330 mg) was added and the mixture was heated to 100°C and reacted for 0.5 hours. LCMS monitored the reaction completion, and the mixture was concentrated under reduced pressure to obtain 650 mg of the crude target compound, which was directly used in the next step without purification. MS (ESI) m / z (M+H) + =287.2.

[0170] Step 3: Preparation of (4,5-diamino-2-phenylthieno[2,3-d]pyrimidin-6-yl)(4-fluoropiperidin-1-yl)methanone

[0171] The crude product of 4,5-diamino-2-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid (650 mg) was dissolved in tetrahydrofuran (30 mL), followed by the addition of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (800 mg), N,N-diisopropylethylamine (410 mg), and 4-fluoropiperidine hydrochloride (220 mg). The mixture was stirred at room temperature for 1 hour. LCMS monitored the reaction completion, and 20 mL of water was added. The mixture was extracted three times with dichloromethane (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 150 mg of the title compound. MS (ESI) m / z (M+H) + =372.2.

[0172] Step 4: Preparation of (9-amino-5-phenyl-2-(trifluoromethyl)imidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(4-fluoropiperidin-1-yl)methanone

[0173] Dissolve (4,5-diamino-2-phenylthieno[2,3-d]pyrimidin-6-yl)(4-fluoropiperidin-1-yl)methanone (100 mg) in N,N-dimethylformamide (8 mL), add 3-bromo-1,1,1-trifluoroacetone (100 mg), and stir in a microwave oven at 100°C for 30 minutes. LCMS monitored the reaction completion, and the system was concentrated under reduced pressure. The residue was purified by Prep-HPLC to obtain the title compound. MS (ESI) m / z (M+H) + =464.2.

[0174] 1 H NMR(400MHz,DMSO-d6)δ8.53(s,1H),7.98-7.96(m,2H),7.72-7.64(m,3H),6.41(s,2H),5.0 3-4.86(m,1H),3.75-3.70(m,2H),3.67-3.61(m,2H),2.04-2.00(m,2H),1.83-1.76(m,2H).

[0175] Example 3: Preparation of (9-amino-5-(pyridin-4-yl)imidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0176] Step 1: Preparation of 4-hydroxy-6-(methylthio)-2-(pyridin-4-yl)pyrimidine-5-carbonitrile

[0177] Ethyl 2-cyano-3,3-bis(methylthio)acrylate (600 mg), benzamidine hydrochloride (400 mg), and potassium carbonate (760 mg) were dissolved in a mixture of acetonitrile and water (ACN:H2O = 4:1 (v / v), 20 mL) and stirred at room temperature for 1 hour. After the disappearance of the starting material as monitored by LCMS, the organic solvent was removed by concentration under reduced pressure. The precipitated solid was filtered, the filter cake washed with water, and dried under vacuum to obtain 500 mg of the title compound. MS (ESI) m / z (M+H) + =245.1.

[0178] Step 2: Preparation of 4-chloro-6-(methylthio)-2-(pyridin-4-yl)pyrimidine-5-carbonitrile

[0179] Dissolve the crude product (500 mg) of 4-hydroxy-6-(methylthio)-2-(pyridin-4-yl)pyrimidine-5-carbonitrile in phosphorus oxychloride (10 mL) and heat to 120°C with stirring for 2 hours. After completion of the reaction as monitored by LCMS, the phosphorus oxychloride was removed by concentration under reduced pressure. The residue was poured into ice water and adjusted to a weak base with saturated NaHCO3 solution. The mixture was extracted three times with ethyl acetate (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 400 mg of the title compound. MS (ESI) m / z (M+H) + =263.1.

[0180] Step 3: Preparation of 4-(methylthio)-6-((2-oxo-2-(piperidin-1-yl)ethyl)thio)-2-(pyridin-4-yl)pyrimidine-5-carbonitrile

[0181] 4-Chloro-6-(methylthio)-2-(pyridin-4-yl)pyrimidine-5-carbonitrile (400 mg) was dissolved in ethanol (20 mL), and a solution of sodium 2-oxo-2-(piperidin-1-yl)ethane-1-thiolate in ethanol and water (2.3 mL, ~1 mmol / mL) was added. The mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction completion, and saturated ammonium chloride solution was added to quench the reaction. The ethanol was removed by concentration under reduced pressure, and the residue was extracted three times with ethyl acetate (30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 350 mg of the title compound. MS (ESI) m / z (M+H) + =386.1.

[0182] Step 4: Preparation of (5-amino-4-(methylthio)-2-(pyridin-4-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0183] 4-(Methylthio)-6-((2-oxo-2-(piperidin-1-yl)ethyl)thio)-2-(pyridin-4-yl)pyrimidine-5-carbonitrile (350 mg) was dissolved in tetrahydrofuran (10 mL). Sodium hydride (70 mg) was added under nitrogen and stirred at room temperature for 1 hour. LCMS monitored the reaction completion. Saturated ammonium chloride solution was added to quench the reaction. The tetrahydrofuran was removed by concentration under reduced pressure, and the residue was extracted three times with ethyl acetate (20 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 300 mg of the title compound. MS (ESI) m / z (M+H) + =386.1.

[0184] Step 5: Preparation of (5-amino-4-((2-hydroxyethyl)amino)-2-(pyridin-4-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0185] (5-Amino-4-(methylthio)-2-(pyridin-4-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (300 mg) and 2-aminoethanol (200 mg) were dissolved in N,N-dimethylacetamide (5 mL) and heated to 140°C in a microwave oven for 3 hours. LCMS monitored the reaction completion. The reaction system was directly purified by reverse phase column chromatography to obtain 200 mg of the title compound. MS (ESI) m / z (M+H) + =399.1.

[0186] Step 6: Preparation of (9-amino-5-(pyridin-4-yl)-2,3-dihydroimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0187] Dissolve (5-amino-4-((2-hydroxyethyl)amino)-2-(pyridin-4-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (200 mg) in dichloromethane (10 mL), add p-toluenesulfonyl chloride (170 mg) and 4-dimethylaminopyridine (200 mg), and stir at room temperature overnight. LCMS monitoring indicates the reaction is complete, and the product is concentrated under reduced pressure. The residue is purified by reverse phase column chromatography to obtain 100 mg of the title compound. MS (ESI) m / z (M+H) + =381.1.

[0188] Step 7: Preparation of (9-amino-5-(pyridin-4-yl)imidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0189] (9-Amino-5-(pyridin-4-yl)-2,3-dihydroimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone (100 mg) and 2,3-dichloro-5,6-dicyanobenzoquinone (180 mg) were dissolved in dichloromethane (5 mL) and stirred at room temperature for 2 hours. The reaction was complete as monitored by LCMS. Water (10 mL) was added to terminate the reaction, and the mixture was extracted three times with dichloromethane (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLC to yield 30 mg of the title compound. MS (ESI) m / z = 379.1 (M+H) + .

[0190] 1 H NMR (400MHz, DMSO-d6) δ8.91(d,J=5.2Hz,2H),8.11(s,1H),7.99(d,J=4.8Hz,2H),7.73(s,1H),6.46(brs,2H),3.64-3.61(m,4H),1.66-1.55(m,6H).

[0191] Example 4: Preparation of (9-iodo-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0192] Step 1: Preparation of 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid

[0193] Ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (1.0 g, 2.2 mmol) was added to a mixture of ethanol and water (EtOH:H2O = 1:1 (v / v), 20 mL). Lithium hydroxide monohydrate (460 mg) was then added. The mixture was heated to 100°C and stirred for 1 hour. The reaction was stopped after completion of the reaction as monitored by LCMS. The system was then concentrated under reduced pressure, and the residue was purified by reverse-phase column chromatography to yield 700 mg of the title compound. MS (ESI) m / z (M+H) + =429.1.

[0194] Step 2: Preparation of (5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0195] Crude 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylic acid (450 mg) was dissolved in a mixture of tetrahydrofuran and N,N-dimethylformamide (THF:DMF = 4:1 (v / v), 10 mL). 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (800 mg), N,N-diisopropylethylamine (410 mg), and piperidine (180 mg) were added and stirred at room temperature for 2 hours. LC-MS indicated complete reaction of the starting material. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 430 mg of the title compound. MS (ESI) m / z (M+H) + =496.2.

[0196] Step 3: Preparation of (4-amino-5-iodo-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0197] (5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (420 mg) was dissolved in ethanol (2 mL), 25% aqueous ammonia (5 mL) was added, and the mixture was stirred in a microwave oven at 120°C for 4 hours. LCMS indicated the reaction was complete. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 150 mg of the crude title compound. MS (ESI) m / z (M+H) + =465.2.

[0198] Step 4: Preparation of (9-iodo-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0199] (4-Amino-5-iodo-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (150 mg) was dissolved in acetonitrile (8 mL), 2-bromo-1,1-diethoxyethane (252 mg) was added, and the mixture was heated to 120°C and stirred for 3 hours in a microwave oven. LCMS showed that the reaction was complete. The system was concentrated under reduced pressure, and the residue was purified by Prep-HPLC to obtain 30 mg of the target compound. MS (ESI) m / z (M+H) + =489.2.

[0200] 1 H NMR (400MHz, DMSO-d6) δ8.03 (d, J = 1.6 Hz, 1H), 7.98-7.94 (m, 2H), 7.73 (d, J = 1.6 Hz, 1H), 7.70-7.63 (m, 3H), 3.66 (brs, 4H), 1.73-1.51 (m, 6H).

[0201] Example 5: Preparation of (9-amino-5-phenylthieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0202] Step 1: Preparation of 4-hydrazino-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile

[0203] Dissolve 4-chloro-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile (0.5 g) in acetonitrile (30 mL), add hydrazine hydrate (0.93 mL), and heat to 90°C for 0.5 hours. LCMS monitoring confirmed the completion of the reaction. The acetonitrile was removed by concentration under reduced pressure, and the reaction was quenched by addition of water. The product was extracted three times with ethyl acetate (8 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.26 g of the title compound. MS (ESI) m / z (M+H) + =258.1.

[0204] Step 2: Preparation of 7-(methylthio)-5-phenyl-[1,2,4]triazolo[4,3-c]pyrimidine-8-carbonitrile

[0205] Dissolve 4-hydrazino-6-(methylthio)-2-phenylpyrimidine-5-carbonitrile (0.26 g) in triethyl orthoformate (8 mL) in a microwave tube, add formic acid (0.1 mL), and stir in a microwave oven at 150°C for 4 hours. After completion of the reaction, LCMS monitoring revealed that the reaction was complete. Saturated ammonium chloride solution was added to quench the reaction, and the product was extracted three times with ethyl acetate (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 0.16 g of the title compound. MS (ESI) m / z (M+H) + =268.1.

[0206] Step 3: Preparation of 7-(methylsulfonyl)-5-phenyl-[1,2,4]triazolo[4,3-c]pyrimidine-8-carbonitrile

[0207] Dissolve 7-(Methylthio)-5-phenyl-[1,2,4]triazolo[4,3-c]pyrimidine-8-carbonitrile (0.16 g) in dichloromethane (6 mL), add m-chloroperbenzoic acid (0.2 g), and stir at room temperature for 1 hour. LCMS monitoring indicates that the reaction is complete. Add saturated ammonium chloride solution to quench the reaction, extract three times with ethyl acetate (10 mL), combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The residue is purified by silica gel column chromatography to obtain 0.1 g of the title compound. MS (ESI) m / z (M+H) + =300.1.

[0208] Step 4: Preparation of 7-((2-oxo-2-(piperidin-1-yl)ethyl)thio)-5-phenyl-[1,2,4]triazolo[4,3-c]pyrimidine-8-carbonitrile

[0209] Dissolve 7-(Methylsulfonyl)-5-phenyl-[1,2,4]triazolo[4,3-c]pyrimidine-8-carbonitrile (0.1 g) in ethanol (2 mL), then add a solution of sodium 2-oxo-2-(piperidin-1-yl)ethane-1-thiolate in ethanol and water (1.3 mL, ~1 mmol / mL). Stir at room temperature for 2 hours. LCMS monitoring indicates that the reaction is complete. Saturated ammonium chloride solution is added to quench the reaction, and the ethanol is removed by concentration under reduced pressure. The residue is extracted three times with ethyl acetate (30 mL). The combined organic phases are dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue is purified by silica gel column chromatography to yield 50 mg of the title compound. MS (ESI) m / z (M+H) + =379.1.

[0210] Step 5: Preparation of (9-amino-5-phenylthieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0211] 7-((2-oxo-2-(piperidin-1-yl)ethyl)thio)-5-phenyl-[1,2,4]triazolo[4,3-c]pyrimidine-8-carbonitrile (50 mg) was dissolved in tetrahydrofuran (10 mL). Sodium hydride (62 mg) was added under nitrogen and stirred in an ice-salt bath for 1 hour. LCMS monitored the reaction completion. Saturated ammonium chloride solution was added to quench the reaction. The tetrahydrofuran was removed by concentration under reduced pressure, and the residue was extracted three times with ethyl acetate (5 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLC to yield 7 mg of the title compound. MS (ESI) m / z (M+H) + =379.1.

[0212] 1H NMR (400MHz, DMSO-d6) δ8.81(s,1H),8.49(d,J=7.5Hz,2H),7.69-7.62(m,3H),6.33(s,2H),3.61(t,J=5.2Hz,4H),1.74-1.51(m,6H).

[0213] Example 6: Preparation of (9-methoxy-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0214] Step 1: Preparation of diethyl 2-(bis(methylthio)methylene)malonate

[0215] 60% sodium hydride (1.5 g) was added to tetrahydrofuran (30 mL). Diethyl malonate (5.0 g) was added under nitrogen protection. The mixture was then cooled to -78°C in a dry ice bath and slowly added dropwise with carbon disulfide (1.87 mL). After the addition was complete, the mixture was stirred and reacted at -78°C for 1 hour. When the system turned light yellow, iodomethane (4.28 mL) was slowly added dropwise. After the addition was complete, the mixture was stirred and reacted at -78°C for 1 hour, then slowly raised to 0°C and reacted for 1 hour. LCMS monitored the reaction completion, quenched the reaction with water, and concentrated under reduced pressure to remove tetrahydrofuran. The residue was poured into ice water and stirred continuously until a yellow solid precipitated. The product was filtered, washed with water, and dried to obtain 6 g of the title compound. MS (ESI) m / z (M+H) + =265.1.

[0216] Step 2: Preparation of ethyl 4-hydroxy-6-(methylthio)-2-phenylpyrimidine-5-carboxylate

[0217] Diethyl 2-(bis(methylthio)methylene)malonate (6.0 g), benzamidine hydrochloride (3.0 g), and potassium carbonate (9.4 g) were dissolved in a mixture of acetonitrile and water (ACN:H2O = 4:1 (v / v), 40 mL) and stirred at room temperature for 1 hour. The reaction was complete as monitored by LCMS. The organic solvent was removed by concentration under reduced pressure to precipitate a solid, which was filtered, washed with water, and dried under vacuum to yield 5 g of the title compound. MS (ESI) m / z (M+H) + =291.1.

[0218] Step 3: Preparation of ethyl 4-chloro-6-(methylthio)-2-phenylpyrimidine-5-carboxylate

[0219] Ethyl 4-hydroxy-6-(methylthio)-2-phenylpyrimidine-5-carboxylate (5g) was added to phosphorus oxychloride (50mL), and the mixture was heated to 100°C with stirring for 2 hours. The reaction was complete as monitored by LCMS. The phosphorus oxychloride was removed by concentration under reduced pressure. The residue was poured into ice water and adjusted to a weak base with saturated NaHCO3 solution. The mixture was extracted three times with ethyl acetate (100mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 1.6g of the title compound. MS (ESI) m / z (M+H) + =309.1.

[0220] Step 4: Preparation of ethyl 4-(methylthio)-6-((2-oxo-2-(piperidin-1-yl)ethyl)thio)-2-phenylpyrimidine-5-carboxylate

[0221] Ethyl 4-chloro-6-(methylthio)-2-phenylpyrimidine-5-carboxylate (1.6 g) was dissolved in ethanol (40 mL), and a solution of sodium 2-oxo-2-(piperidin-1-yl)ethane-1-thiolate in ethanol and water (6.5 mL, ~1 mmol / mL) was added. The mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction completion, and saturated ammonium chloride solution was added to quench the reaction. The ethanol was removed by concentration under reduced pressure, and the residue was extracted three times with ethyl acetate (30 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 2 g of the title compound. MS (ESI) m / z (M+H) + =432.1.

[0222] Step 5: Preparation of (5-hydroxy-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0223] Ethyl 4-(methylthio)-6-((2-oxo-2-(piperidin-1-yl)ethyl)thio)-2-phenylpyrimidine-5-carboxylate (2.0 g) was dissolved in tetrahydrofuran (40 mL). 60% sodium hydride (0.33 g) was added under nitrogen and stirred in an ice-salt bath for 1 hour. The reaction was complete as monitored by LCMS. Saturated ammonium chloride solution was added to quench the reaction. The tetrahydrofuran was removed by concentration under reduced pressure, and the residue was extracted three times with ethyl acetate (20 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 1.8 g of the title compound. MS (ESI) m / z (M+H) + =386.1.

[0224] Step 6: Preparation of (5-methoxy-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0225] (5-Hydroxy-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (0.4 g) was dissolved in tetrahydrofuran (8 mL), and iodomethane (0.74 g) and 60% sodium hydride (0.12 g) were added. The mixture was heated to 80°C and stirred in a microwave oven for 40 minutes. LCMS monitored the reaction completion, and saturated ammonium chloride solution was added to quench the reaction. The mixture was extracted three times with ethyl acetate (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.36 g of the title compound. MS (ESI) m / z (M+H) + =400.1.

[0226] Step 7: Preparation of (5-methoxy-4-(methylsulfonyl)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0227] Dissolve (5-methoxy-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (0.36 g) and m-chloroperbenzoic acid (0.62 g) in dichloromethane (8 mL) and stir at room temperature for 1 hour. LCMS monitored the reaction completion, quenched by adding saturated ammonium chloride solution, and extracted three times with ethyl acetate (5 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.2 g of the title compound. MS (ESI) m / z (M+H) + =432.1.

[0228] Step 8: Preparation of (4-amino-5-methoxy-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0229] (5-Methoxy-4-(methylsulfonyl)-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (0.39 g) was dissolved in N,N-dimethylacetamide (8 mL), 25% aqueous ammonia (0.5 mL) was added, and the mixture was heated to 80°C and stirred for 30 minutes in a microwave oven. LCMS monitored the reaction completion, and saturated ammonium chloride solution was added to quench the reaction. The mixture was extracted three times with ethyl acetate (10 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 0.25 g of the title compound. MS (ESI) m / z (M+H) + =369.1.

[0230] Step 9: Preparation of (9-methoxy-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0231] Dissolve (4-amino-5-methoxy-2-phenylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (60 mg) in acetonitrile (8 mL), add 2-bromo-1,1-dimethoxyethane (0.27 g), and microwave at 120°C for 3 hours. LCMS monitored the reaction completion, quenched by addition of saturated ammonium chloride solution, and extracted three times with ethyl acetate (5 mL). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-HPLC to yield 10 mg of the title compound. MS (ESI) m / z (M+H) + =393.1.

[0232] 1 H NMR (400MHz, DMSO-d6) δ8.01(d,J=1.6Hz,1H),7.97-7.94(m,2H),7.74-7.61(m,4H),4.16(s,3H),3.57(brs,4H),1.66-1.57(m,6H).

[0233] Examples 7 to 21

[0234] Using the corresponding commercial reagents and the products of the above preparation examples and examples as raw materials, a class of compounds were prepared using a preparation method similar to the above examples. The structures and characterization data of the compounds are shown in Table 1:

[0235] Table 1

[0236] Example 22: Preparation of (9-iodo-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0237] Dissolve (9-iodo-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone (15.0 mg) in N,N-dimethylformamide (3 mL). Add cuprous iodide (6.0 mg) and cuprous cyanide (5.5 mg). Replace with argon and heat to 90°C with stirring for 2 hours. Upon completion of the reaction as monitored by LCMS, the system was concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford 3 mg of the title compound.

[0238] MS (ESI) m / z (M+H) +=388.1.

[0239] 1 H NMR (400MHz, DMSO-d6) δ8.13(d,J=1.5Hz,1H),8.03-7.94(m,2H),7.79(s,1H),7.70(dq,J=14.0,6.9Hz,3H),3.59(s,4H),1.64(d,J=20.2Hz,6H).

[0240] Example 23: Preparation of (9-isopropyl-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0241] Step 1: Preparation of ethyl 4-(methylthio)-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidine-6-carboxylate

[0242] Ethyl 5-iodo-4-(methylthio)-2-phenylthieno[2,3-d]pyrimidine-6-carboxylate (300 mg) was dissolved in a mixture of dioxane and water (Dioxane:H2O = 4:1). Potassium carbonate (182 mg), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (48 mg), and isopropenylboronic acid pinacol ester (220.1 mg) were added. The atmosphere was purged with nitrogen three times, and the temperature was raised to 90°C, followed by stirring for 4 hours. The reaction was complete as monitored by LCMS. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound. MS (ESI) m / z (M+H) + =371.1.

[0243] Step 2: Preparation of 4-(methylthio)-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidine-6-carboxylic acid

[0244] Ethyl 4-(methylthio)-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidine-6-carboxylate (160 mg) was dissolved in a mixture of ethanol and water, followed by the addition of lithium hydroxide monohydrate (90 mg). The mixture was heated to 100°C and stirred for 1 hour. LCMS monitoring confirmed the completion of the reaction and the reaction was stopped. The system was directly concentrated under reduced pressure, and the residue was purified by reverse phase column chromatography to obtain the title compound. MS (ESI) m / z (M+H) + =343.1.

[0245] Step 3: Preparation of (4-(methylthio)-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0246] Dissolve 4-(Methylthio)-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidine-6-carboxylic acid (200 mg) in N,N-dimethylformamide (12 mL). Add 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (441.1 mg), N,N-diisopropylethylamine (149.9 mg), and piperidine (98.8 mg). Stir and react at room temperature overnight. LC-MS indicated complete reaction of the starting material. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound. MS (ESI) m / z (M+H) + =410.1.

[0247] Step 4: Preparation of (4-amino-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0248] Dissolve (4-(methylthio)-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (120 mg) in N-methylpyrrolidone (2 mL), add aqueous ammonia (4 mL), and stir in a microwave at 150°C for 6 hours. After LC-MS showed that most of the starting material had disappeared, the reaction was stopped. The system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound. MS (ESI) m / z (M+H) + =379.2.

[0249] Step 5: Preparation of (4-amino-2-phenyl-5-isopropylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone

[0250] Dissolve (4-amino-2-phenyl-5-(prop-1-en-2-yl)thieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (100 mg) in tetrahydrofuran (10 mL), add palladium on carbon (28.1 mg), and stir at room temperature for 10 hours. LC-MS indicates the reaction is complete, and the reaction is stopped. The system is concentrated under reduced pressure, and the residue is purified by silica gel column chromatography to obtain the title compound. MS (ESI) m / z (M+H) + =381.2.

[0251] Step 6: Preparation of (9-isopropyl-5-phenylimidazo[1,2-c]thieno[3,2-e]pyrimidin-8-yl)(piperidin-1-yl)methanone

[0252] Dissolve (4-amino-2-phenyl-5-isopropylthieno[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone (30 mg) in acetonitrile (4 mL), add 2-bromo-1,1-diethoxyethane (67.1 mg), and stir in a microwave oven at 120°C for 3 hours. LC-MS showed the disappearance of the starting material, and the reaction was stopped. The system was concentrated under reduced pressure, and the residue was purified by Prep-HPLC to obtain the title compound. MS (ESI) m / z (M+H) + =405.2.

[0253] 1 H NMR (400MHz, DMSO-d6) δ7.99(d,J=1.6Hz,1H),7.98-7.93(m,2H),7.71(d,J=1.6Hz,1H),7.70-7.62(m,3H ),3.88-3.81(m,1H),3.65(s,2H),3.37(s,2H),1.64(d,J=5.7Hz,2H),1.56(s,4H),1.50(d,J=7.0Hz,6H).

[0254] Example 24: Preparation of 5-(9-amino-8-(piperidine-1-carbonyl)imidazo[1,2-c]thieno[3,2-e]pyrimidin-5-yl)-2-methylisoindol-1-one

[0255] Step 1: Preparation of 4-amino-2-(2-methyl-1-oxoisoindolin-5-yl)-6-(methylthio)pyrimidine-5-carbonitrile

[0256] 4-Amino-2-chloro-6-(methylthio)pyrimidine-5-carbonitrile (1.50 g) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (2.04 g) were added to 1,4-dioxane (20 mL) and water (2.0 mL). Cesium carbonate (3.65 g) and 1,1-bis(diphenylphosphino)ferrocenepalladium chloride (610 mg) were added under nitrogen. The reaction was stirred at 100°C for 12 hours. LCMS indicated completion of the reaction. Dimethyl sulfoxide was added to the reaction mixture, and the mixture was stirred at 40°C for 0.5 hours. After complete dissolution, it was filtered. 200 mL of water was added to the filtrate, and the mixture was stirred for 0.5 hours, resulting in the precipitation of a solid. The mixture was filtered, and the filter cake was rinsed with 50 mL of water (2 x 50 mL). The solid was then dried to obtain the crude product. The crude product was separated and purified again using prep-HPLC to obtain the title compound. MS (ESI) m / z (M+H) + =312.2.

[0257] Step 2: Preparation of 5-(2-methyl-1-oxoisoindolin-5-yl)-7-(methylthio)imidazo[1,2-c]pyrimidine-8-carbonitrile

[0258] 4-Amino-2-(2-methyl-1-oxoisoindolin-5-yl)-6-(methylthio)pyrimidine-5-carbonitrile (0.5 g) and 2-bromo-1,1-diethoxyethane (2 mL) were added to a microwave tube. Acetonitrile (10 mL) was added to the microwave tube. The reaction was allowed to proceed under microwave irradiation for 1.5 hours. TLC and LCMS showed that the reaction was complete. The reaction solution was adjusted to a weak base with saturated sodium bicarbonate solution and extracted several times with DCM:MeOH=10:1 (V / V). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified on a silica gel column to obtain the title compound. MS (ESI) m / z (M+H) + =336.1.

[0259] Step 3: Preparation of 7-methanesulfonyl-5-(2-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl)imidazo[1,2-c]pyrimidine-8-carbonitrile

[0260] 5-(2-methyl-1-oxoisoindolin-5-yl)-7-(methylthio)imidazo[1,2-c]pyrimidine-8-carbonitrile (0.15 g) was added to chloroform (5 mL). 3-Chloroperoxybenzoic acid (300 mg) was added at 20°C. The reaction solution was stirred at 45°C for 3 hours. LCMS confirmed the completion of the reaction. The reaction solution was poured into a saturated aqueous sodium carbonate solution and extracted with dichloromethane. The organic phase was dried, concentrated, and purified on a silica gel column to obtain the title compound (70 mg). MS (ESI) m / z (M+H)+ =368.0.

[0261] Step 4: Preparation of 5-(2-methyl-1-oxoisoindol-5-yl)-7-((2-oxo-2-(piperidin-1-yl)ethyl)thio)imidazo[1,2-c]pyrimidine-8-carbonitrile

[0262] Dissolve 7-methylsulfonyl-5-(2-methyl-1-oxo-2,3-dihydro-1H-isoindol-5-yl)imidazo[1,2-c]pyrimidine-8-carbonitrile (100 mg) in DMF, add sodium hydrosulfide (43.25 mg, Purity 70%), and react at 50°C for 30 minutes. LCMS monitoring indicates the reaction is complete. Add 2-chloro-1-(piperidin-1-yl)ethan-1-one (87.28 mg) and continue the reaction for 1 hour. LCMS monitoring indicates the reaction is complete. Cool to room temperature, dilute with water, extract with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, concentrate, and purify on a silica gel column to obtain the title compound. MS (ESI) m / z (M+H) + =447.0.

[0263] Step 5: Preparation of 5-(9-amino-8-(piperidine-1-carbonyl)imidazo[1,2-c]thieno[3,2-e]pyrimidin-5-yl)-2-methylisoindol-1-one

[0264] Dissolve 5-(2-methyl-1-oxoisoindol-5-yl)-7-((2-oxo-2-(piperidin-1-yl)ethyl)thio)imidazo[1,2-c]pyrimidine-8-carbonitrile (35 mg) in dry tetrahydrofuran. Add lithium bis(trimethylsilyl)amide (0.2 mL, 1 M) under an ice-water bath. Move to room temperature and react for 4 hours. LCMS and TLC monitor the reaction for completion. Quench, extract with ethyl acetate, and dry, then separate on a reverse-phase preparative column to obtain the title compound. MS (ESI) [M+H] + =:447.1.

[0265] 1 H NMR (400MHz, DMSO-d6) δ8.17(s,1H),8.07-8.04(m,2H),7.91-7.89(d,J=7.9Hz,1H),7.70(d ,J=1.6Hz,1H),6.48(s,2H),4.61(s,2H),3.63-3.60(m,4H),3.14(s,3H),1.64-1.58(m,6H).

[0266] Example 25: Preparation of 6-(9-amino-8-(piperidine-1-carbonyl)imidazo[1,2-c]thieno[3,2-e]pyrimidin-5-yl)-2-methylisoquinolin-1(2H)-one

[0267] The title compound was prepared in a similar manner to Reference Example 24.

[0268] MS (ESI) [M+H] + =:459.1. 1 H NMR (400MHz, DMSO-d6) δ8.44-8.42(d,J=8.4Hz,1H),8.29(d,J=1.7Hz,1H),8.09(d,J=1.7Hz,1H),8.03-8.00(dd,J=8.4,1.8Hz,1H),7. 71(d,J=1.6Hz,1H),7.63-7.60(d,J=7.3Hz,1H),6.81(d,J=7.4Hz,1H),6.49(s,2H),3.63-3.60(m,4H),3.57(s,3H),1.65-1.58(m,6H).

[0269] Biological tests

[0270] Test Example 1: 15-PGDH kinase activity detection

[0271] 1. Experimental Materials:

[0272] 2. Experimental methods:

[0273] a. Prepare a reaction buffer solution containing 50 mM Tris-HCl, 0.01% Tween 20, pH 7.5 with ultrapure water;

[0274] b. Prepare a 10 mM stock solution of the test compound using DMSO. Then dilute the stock solution with reaction buffer to obtain a 40,000 nM solution of test compound 1. Serially dilute solution 1 in a three-fold gradient to obtain 9 (or 11) concentrations of test compound solutions 2 to 9 (or 2 to 12). Add 5 μL of each concentration of test compound solution to a 384-well plate as an experimental well.

[0275] c. Add 5 μL of reaction buffer to the blank wells of the 384-well plate as positive control wells and blank control wells, respectively.

[0276] d. Prepare a 15-PGDH protein solution at a concentration of 5 ng / μL using reaction buffer. Add 5 μL of 15-PGDH protein solution to the experimental wells and positive control wells. Add 5 μL of reaction buffer to the blank control wells, and then centrifuge the plate at 2000 rpm for 30 seconds.

[0277] e. Prepare 5 mM β-NAD and 2 mM PGF2α in reaction buffer, mix them at a volume ratio of 1:1 to prepare a substrate mixture. Add 10 μL of the substrate mixture to the experimental wells, positive control wells, and blank control wells to start the reaction.

[0278] f. Use a multifunctional microplate reader to continuously detect the fluorescence signal value of each well (Ex / Em=340 / 450).

[0279] 3. Data Analysis:

[0280] a) Analyze the continuous fluorescence signal values ​​using the "kinetic calculations-slope calculation method" in PHERAstar Data analysis software to obtain the slope of each experimental well;

[0281] b) Calculate the inhibition rate (%) using the following formula: Inhibition rate (%) = [1 - (slope of experimental well - signal value of positive control well) / (signal value of blank control well - average signal value of positive control well)] x 100%.

[0282] c) Calculation of IC50 and plotting of inhibition-dose curves: GraphPad Prism 6.0 was used to fit compound concentration and corresponding inhibition rate using a nonlinear regression (dose-response - variable slope) to calculate the IC50 value. The formula is as follows: Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) * HillSlope)), where X is the logarithm of compound concentration and Y is the inhibition rate.

[0283] 4. The test results of the compounds in the examples of this application are as follows:

[0284] In the table, “A” represents the IC of 15-PGDH enzyme inhibition activity 50 The range is less than 3 nM; "B" represents the IC of 15-PGDH enzyme inhibition activity 50 The range is greater than or equal to 3 nM and less than 10 nM; "C" represents the IC of 15-PGDH enzyme inhibition activity 50 The range is greater than or equal to 10nM and less than 25nM; "D" represents the IC of 15-PGDH enzyme inhibition activity 50The range is greater than or equal to 25 nM and less than 50 nM.

[0285] The compounds of the present application can exhibit inhibitory activity against 15-PGDH enzyme. The IC values ​​of the compounds of the present application for the inhibitory activity against 15-PGDH enzyme are 50 The value may be less than 100 nM. The IC values ​​of some compounds in this application for 15-PGDH enzyme inhibition activity are 50 The IC values ​​of some compounds in this application for 15-PGDH enzyme inhibition are greater than or equal to 20 nM and less than 50 nM. 50 The IC values ​​of some compounds of the present invention for 15-PGDH enzyme inhibition are greater than or equal to 10 nM and less than 20 nM. 50 The IC values ​​of certain compounds of the present invention for 15-PGDH enzyme inhibition are greater than or equal to 3 nM and less than 10 nM. 50 The IC values ​​of certain compounds of the present invention for 15-PGDH enzyme inhibition are greater than or equal to 1.5 nM and less than 3 nM. 50 For example, the IC value of the compound of Example 1 for 15-PGDH enzyme inhibition activity is less than 1.5 nM. 50 The value was less than 1.5 nM.

[0286] Test Example 2: Intracellular PGE2 upregulation activity assay

[0287] 1. Experimental Materials:

[0288] 2. Experimental methods:

[0289] a) A549 cells were seeded in 24-well plates and stimulated with IL-1β for 16 h after cell attachment to induce COX2 expression and PGE2 production.

[0290] b) Prepare a test compound solution in culture medium and serially dilute to 3 concentrations of 10 nM, 300 nM, and 10,000 nM or to 7 concentrations of 0.64 nM, 3.2 nM, 16 nM, 80 nM, 400 nM, 2,000 nM, and 10,000 nM. Simultaneously, set up a positive control group (only IL-1β was added to the cells for induction) and a negative control group (only cells were added to the wells without any treatment). After 8 hours of action, the cell supernatant was collected. The positive control group was induced with IL-1β but not treated with the compound, and the negative control group was not stimulated with IL-1β and not treated with the compound.

[0291] c) The PGE2 content of the sample was determined using a Prostaglandin E2 Kit, and the fluorescence signal was detected by a multifunctional microplate reader (Ex / Em=337 / 620, 337 / 665).

[0292] 3. Data Analysis:

[0293] a) Use the PGE2 standard in the "Prostaglandin E2 Kit" to draw a standard curve and substitute the sample fluorescence signal to calculate the PGE2 concentration.

[0294] b) The PGE2 up-regulation ratio (%) was calculated using the following formula: PGE2 up-regulation ratio (%) = (PGE2 concentration in the sample group / PGE2 concentration in the positive control group) × 100%.

[0295] 4. Experimental Results

[0296] The compounds of the present application can upregulate PGE2 in A549 cells by a ratio of >100%, certain compounds of the present application can upregulate PGE2 in A549 cells by a ratio of >200%, and certain preferred compounds of the present application can upregulate PGE2 in A549 cells by a ratio of >300% or higher. For example, embodiment 8 is respectively 483%, 520%, 770% to the up-regulation ratio of PGE2 in A549 cells when compound concentration is 16nM, 80nM, 400nM; embodiment 24 is respectively 568%, 461%, 473% to the up-regulation ratio of PGE2 in A549 cells when compound concentration is 3.2nM, 16nM, 80nM; embodiment 25 is respectively 513%, 782%, 741% to the up-regulation ratio of PGE2 in A549 cells when compound concentration is 3.2nM, 16nM, 80nM; embodiment 9, embodiment 21 are respectively 333%, 321% to the up-regulation ratio of PGE2 in A549 cells when compound concentration is 400nM. The present application compound can have the activity of good PGE2 in the up-regulation cell.

[0297] For the purposes of description and disclosure, all patents, patent applications, and other publications are expressly incorporated herein by reference. These publications are provided solely because their disclosure predates the filing date of the present application. All statements regarding the dates of these documents or the representations of their contents are based on information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any citation of these publications herein does not constitute an admission that such publications become part of the common general knowledge in the art in any country.

[0298] Those skilled in the art will recognize that the scope of the present application is not limited to the various specific implementation plans and examples described above, but that various modifications, replacements, or recombinations can be made without departing from the spirit of the present application, and these adjusted solutions fall within the scope of protection of the present application.

Claims

1. A compound represented by formula (I), its stereoisomers, tautomers or mixtures thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof: Ring A is selected from aromatic rings, aromatic heterocycles, and unsaturated aliphatic heterocycles, L and G are each independently selected from C1 to C 10 A chain hydrocarbon group, or L, G and the nitrogen atom to which they are connected together form a cyclic group, wherein the cyclic group is a 3-12-membered saturated aliphatic heterocycle or a ring formed by combining a 3-12-membered saturated aliphatic heterocycle and a benzene ring, o is selected from 0, 1, 2, 3, R 1 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, halogen, cyano, =O, imino, amine, ester, aldehyde, carboxyl, amide, C3-C8 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, 3-8 membered saturated heterocyclic group, or when o is selected from 2, 3, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 3- to 8-membered alicyclic group or a 3- to 8-membered alicyclic group, is a single bond or a double bond, and when When it is a double bond, X and Y are each independently selected from CR B or N; when When it is a single bond, X and Y are CR C R D , R A 、R B 、R C 、R D Each is independently selected from hydrogen, hydroxyl, halogen, amino, cyano, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; in, The aromatic heterocycle, saturated aliphatic heterocycle, unsaturated aliphatic heterocycle, and aliphatic heterocyclic group each independently contain 1 to 3 heteroatoms, wherein the heteroatoms are independently selected from N, O, and S, and the saturated aliphatic heterocycle contains at least 1 nitrogen atom; The L, G, R 1 Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, aldehyde, amine, imine, halogen, cyano, ester, carboxyl, amide, =O, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

2. The compound according to claim 1, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: The R 1 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, halogen, cyano, =O, imino, amine, ester, aldehyde, carboxyl, amide, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, 3-8 membered saturated heterocyclic group, or when o is selected from 2, 3, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a 3-8 membered alicyclic group or a 3-8 membered alicyclic heterocyclic group, wherein R 1 Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, aldehyde, amine, imine, halogen, cyano, ester, carboxyl, amide, =O, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

3. The compound according to claim 1 or 2, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: The L and G are each independently selected from C1 to C 10 Alkyl, wherein L and G are optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, aldehyde, amine, imine, halogen, cyano, ester, carboxyl, amide, =O, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl; preferably, L and G are each independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, hydroxymethyl, hydroxyethyl, and hydroxypropyl.

4. The compound according to claim 1 or 2, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: The compound is shown in formula (II): Ring B is a 3- to 12-membered saturated aliphatic heterocyclic ring or a ring formed by combining a 3- to 12-membered saturated aliphatic heterocyclic ring and a benzene ring. wherein the aromatic heterocycle, saturated aliphatic heterocycle, unsaturated aliphatic heterocycle, and aliphatic heterocyclic group each independently contain 1 to 3 heteroatoms, the heteroatoms being independently selected from N, O, and S, and ring B contains at least 1 nitrogen atom; The ring B, R 1 are optionally independently selected from deuterium, tritium, nitro, hydroxyl, aldehyde, amine, imine, halogen, cyano, ester, Substituted by one or more of carboxyl, amide, =O, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, and 5-10 membered heteroaryl; The ring B is a monocyclic ring, a fused ring, a bridged ring or a spiro ring.

5. The compound according to claim 4, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: Ring B is selected from Wherein, Z is selected from covalent bond, O, S, NH, (CH2) n , SO2; m is selected from 0, 1, 2, 3; R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, halogen, amine, ester, aldehyde, carboxyl, amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl; wherein n is selected from 1, 2, or 3; Preferably, the ring B is selected from 6. The compound according to claim 5, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: The R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, fluorine, chlorine, bromine, amino, ester, aldehyde, carboxyl, amide, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclobutyl, cyclopropyl, phenyl, and pyridyl.

7. The compound according to any one of claims 1, 2 or 4, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: The compound has a structure as shown in Formula III, wherein Z is selected from a covalent bond, S, CH2, (CH2)2 or (CH2)3, m is selected from 0, 1, 2, R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, halogen, amine, ester, aldehyde, carboxyl, amide, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl; Preferably, the R 2 Each is independently selected from deuterium, tritium, nitro, hydroxyl, thiol, cyano, fluorine, chlorine, bromine, amino, ester, aldehyde, carboxyl, amide, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclobutyl, cyclopropyl, phenyl, and pyridyl.

8. The compound according to claim 7, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: The Z is a covalent bond or CH2.

9. The compound according to any one of claims 1 to 8, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, wherein: Is a single bond, and X, Y are CR C R D , the R C 、R D Independently selected from hydrogen, hydroxy, cyano, halogen, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

10. The compound according to any one of claims 1 to 8, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, wherein: is a double bond, and at least one of X and Y is selected from CR B , the R B is selected from hydrogen, hydroxy, cyano, halogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; Preferably, X and Y are both CR B , the R B is selected from hydrogen, hydroxy, cyano, halogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; more preferably, the R B Selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl; Or preferably, Y is selected from N, X is selected from CR B , the R B is selected from hydrogen, hydroxy, cyano, halogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; more preferably, the R B Selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl; Or preferably, X is selected from N, Y is selected from CR B , the R B is selected from hydrogen, hydroxy, cyano, halogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; more preferably, the R B Selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

11. The compound according to any one of claims 1 to 10, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, wherein: The R A Selected from hydrogen, hydroxy, cyano, fluorine, chlorine, bromine, iodine, -NH2, methyl, ethyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl.

12. The compound according to any one of claims 1 to 11, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, wherein: The ring A is selected from a 6-10 membered aromatic ring, a 5-10 membered aromatic heterocycle, or a 6-8 membered unsaturated aliphatic heterocycle; preferably, the aromatic ring or aromatic heterocycle is a monocyclic or fused ring, the unsaturated aliphatic heterocycle is a monocyclic ring, and the aromatic heterocycle and unsaturated aliphatic heterocycle each independently contain 1-3 heteroatoms, and the heteroatoms are independently selected from N, O, and S; more preferably, the ring A is a benzene ring, a naphthalene ring, or a 5-10 membered aromatic heterocycle containing 1-2 heteroatoms, and the heteroatoms are independently N or S; Further preferably, the ring A is selected from 13. The compound according to any one of claims 1 to 12, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, wherein: R 1 R is independently selected from deuterium, tritium, nitro, hydroxyl, sulfhydryl, halogen, cyano, =0, imino, amine, ester, aldehyde, carboxyl, amide, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methyl, ethyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dioxhexyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentyl, tert-pentoxy, n-hexyl, or any two R 1 The atoms of the ring A to which it is connected together form a dioxanyl, dioxolane, dioxinyl, dioxolenyl, dihydropyridinyl, pyrrolinyl, wherein R 1 Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, -NH2, thiol, halogen, cyano, ester, carboxyl, amide, =O, =NH, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

14. The compound according to any one of claims 1 to 12, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, wherein: R 1 R is independently selected from deuterium, tritium, nitro, hydroxyl, sulfhydryl, halogen, cyano, =0, imino, amine, ester, aldehyde, carboxyl, amide, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methyl, ethyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dioxhexyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy, isopentyl, tert-pentoxy, n-hexyl, or any two R 1 The atoms of the ring A to which it is connected together form a dioxanyl group or a dioxolane group, wherein R 1 Optionally substituted by one or more independently selected from deuterium, tritium, nitro, hydroxyl, -NH2, thiol, halogen, cyano, ester, carboxyl, amide, =O, =NH, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl.

15. The compound according to claim 7 or 8, its stereoisomer, tautomer or mixture thereof, or its pharmaceutically acceptable salt, or its solvate, or its prodrug, wherein: The ring A is a benzene ring, a naphthalene ring, or a 5-10 membered aromatic heterocycle containing 1-2 heteroatoms, wherein the heteroatoms are independently N or S; o is 0 or 2. When o is 2, any two R 1 Together with the atoms of the ring A to which it is connected, it forms a saturated or unsaturated 5- to 6-membered cyclic amide group, wherein the nitrogen atom of the cyclic amide group is optionally substituted by a C1-C6 alkyl group; described Is a single bond, and X, Y are CR C R D , the R C 、R D are independently selected from hydrogen, hydroxy, or C1-C6 alkyl, or described is a double bond, and at least one of X and Y is selected from CR B , the R B Selected from hydrogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 haloalkyl; R A is selected from hydrogen, halogen, amino, cyano, C3-C6 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, such as R A Selected from hydrogen, fluorine, chlorine, bromine, iodine, -NH2, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, trifluoromethyl, trifluoroethyl, trichloromethyl, trichloroethyl, cyclopropyl, cyclobutyl, cyclopentyl; Said Z is a covalent bond or CH2; The m is 0, 1 or 2; The R 2 Each is independently selected from fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl.

16. The compound according to any one of claims 1 to 15, its stereoisomers, tautomers or mixtures thereof, or its pharmaceutically acceptable salts, or its solvates, or its prodrugs, wherein: The compound is selected from the following:

17. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 16, or a tautomer or a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a prodrug thereof, and at least one pharmaceutically acceptable excipient.

18. A compound according to any one of claims 1 to 16, a stereoisomer, a tautomer or a mixture thereof, or a pharmaceutically acceptable salt, or a solvate, or a prodrug thereof, or a pharmaceutical composition according to claim 17 for use as a medicament; Preferably, the drug is a 15-PGDH enzyme inhibitor; More preferably, the medicament is used to treat or prevent fibrosis, oral ulcers, gum diseases, colitis, ulcerative colitis, gastroduodenal ulcers, inflammatory diseases, vascular insufficiency, Raynaud's disease, Buerger's disease, neuropathy, pulmonary hypertension, cardiovascular disease and kidney disease, cardiovascular disease, trauma, skin injury, autoimmune disease, graft-versus-host disease, osteoporosis, ear disease, eye disease, neutropenia, diabetes, underactive bladder, or for promoting hair growth, pigmentation, tissue repair, tissue regeneration, implant promotion in stem cell transplantation, bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death or muscle regeneration and cervical ripening, or for enhancing resistance to the toxicity of chemotherapy and the toxicity of immunosuppressants.